Dual mode accommodative-disaccomodative intraocular lens

Information

  • Patent Grant
  • 10512535
  • Patent Number
    10,512,535
  • Date Filed
    Wednesday, August 23, 2017
    7 years ago
  • Date Issued
    Tuesday, December 24, 2019
    5 years ago
Abstract
Embodiments of the invention relate to a flexible, shape-shifting optic adapted to cooperate with a zonular capture haptic system and produce accommodation power both by shape shifting and axial shifting. The optic is designed as a small, thin walled optic vesicle comparable in size to current rigid monofocal IOL optics.
Description
FIELD OF THE INVENTION

Embodiments of the present invention relate generally to intraocular lenses. More particularly, embodiments of the invention relate to accommodative and disaccommodative intraocular lens systems (AD-IOL) and a shape shifting flexible optic adapted to couple with a zonular capture haptic system. The combined features of this flexible optic and zonular capture system haptic system result in a novel, dual mode AD-IOL in which the optic shifts both in shape and in position inside the eye, mimicking the behavior of the natural lens, with the small optic adapted to function in the closed and fibrosed capsular bag that results from conventional cataract surgery.


BACKGROUND

Under normal conditions, a healthy human eye focuses on near and distant objects by contraction and relaxation of the ciliary muscle thereby contracting and releasing the tension on the zonules in the eye. The elastic forces of the eye cause disaccommodation and the elastic recoil of the lens caused accommodation. The balance between these two opposing elastic forces is modulated by the neurologically controlled contraction of the ciliary body. The contraction of the ciliary muscle releases zonular tension (accommodative state) and allows the lens to return to a more globular or spherical resting shape. The relaxation of the ciliary muscle increases tension on zonules and elastic forces in the eye tissue overcome the inherent lens elasticity and result in stretching the lens equator and flattening the lens curvature (disaccommodative state).


In certain instances, for example when age-related opacification of the lens (cataract) interferes with vision, the natural crystalline lens of the eye needs to be removed. Generally, the natural lens is replaced with an artificial one, for example, an intraocular lens (IOL).


Unfortunately, conventional IOLs, and currently FDA approved accommodative IOLs, may be unable to provide sufficient spatial displacement of the lens along the optical axis to provide an adequate amount of accommodation for near vision. For an accommodative IOL to be effective, it preferably provides equally for both accommodation and disaccommodation.


In conventional extracapsular cataract surgery, the crystalline lens matrix is removed by phacoemulsification through a curvilinear capsularhexis leaving intact the thin walls of the anterior and posterior capsules, together with zonular ligament connections to the ciliary body and ciliary muscles. An intraocular lens is then placed in the capsular bag, which collapses around the IOL. A conventional monofocal IOL is rigidly fixated in the nonmoving and fibrosed capsular bag. The position of the IOL in the capsular bag is neither in the accommodated or disaccommodated state, but somewhere in between, as determined by the amount of bag contraction and IOL design. This position is called “effective lens position” and it is utilized in calculating the power of the desired optic. The power of the optic determines the single point of perfectly focused vision, often selected at a practical arm length range.


Conventional axial shifting accommodative intraocular lenses (AIOL) rely on the interaction of the ciliary muscle with the zonule and capsule and the vitreous fluid compartment to induce movement of the optic of the AIOL along its optical axis. Typically, the AIOL is secured within the capsular bag that attempts to translate both the rotational and the radial stretching force exerted by the zonules in an attempt to achieve the desired axial displacement of the optic.


However, during the post-implantation fibrotic healing process, the anterior capsule fuses with the posterior capsule to form a rigid capsular disc, a strait jacket for the AIOL. Loss of elasticity of the capsular disc results and constrains the amount of movement, both centrifugal and rotational, that can be generated by the eye disaccommodation forces transmitted to the IOL via zonules or by the elastic recoil of the intraocular lens within the bag and therefore, leads to a decrease in the amount of axial displacement of the lens that can be achieved. The lens neither accommodates nor disaccommodates.


Various lens systems have been designed to address this loss of accommodation. One type of passive-shift single-optic lens, the only accommodative lens currently marketed in the United States, was designed to move forward under vitreous humor pressure when presumably the ciliary muscle contracts and forces vitreous forward. Even the limited amount of accommodative amplitudes generated by this lens immediately after surgery may be lost within the first few weeks or month after surgery as capsular fibrosis ensues and sometimes the movement is backwards. No passive shift AIOLs are marketed in the US that translate ciliary muscle contraction into forward shift of the optic by direct mechanical action of the haptics.


Accommodative lens designs with single or multiple optic lens assemblies have been disclosed, for example, in U.S. Patent Publication Nos. 2009/0125106, 2005/0209692, 2007/0156236, 2009/0005866, 2007/0005136, and 2009/0248154. Dual optic lenses retain the problem of capsular fibrosis and loss of amplitude/movement even though they are theoretically expected to provide a significant amount of accommodation. One such IOL received regulatory approval in Europe, but was abandoned and withdrawn from the market because of poor and unpredictable clinical results. This lens did not receive FDA approval and currently this approach appears to have been abandoned.


More recently, a lens systems that employs an active-shift mechanism using repulsive mini-magnets as a means of making accommodation partially independent of the zonules and mechanical properties of the capsular bag was disclosed (see U.S. Patent Publication Nos. 2009/0204210 and 2007/0118216). Still other methods of achieving accommodation include introduction of a polymerizable fluid with a desired refractive index into the capsular bag (lens refilling). Extensive investigation into the feasibility of these methods is still needed.


U.S. Patent Publication No. 2009/0234449 discloses an intraocular lens having an accommodating element that is in contact with a substantial portion of the zonular contact region of the ciliary body; the accommodating element is positioned relative to optical element and configured to cooperate with the ciliary muscle, the zonules and/or the vitreous pressure in the eye to effect a shape change to the optical element. According to the '449 publication, prior art multiple lens systems can be cumbersome and may also require an axial displacement unachievable with a collapsed capsular bag and resulting ineffective accommodative mechanisms.


More recently, a lens system has been described that employs a novel zonular capture haptic (ZCH) (see U.S. Patent Publication No. 2011/0307058, incorporated herein by reference in its entirety). The lens system provides improved accommodation via a two stage procedure. In the implantation step, Stage 1, a specially designed sectionable haptic, i.e., a ZCH, is inserted between the anterior and posterior lens capsules and it is maintained in a restrained configuration. Sufficient time is allowed for fusion and fibrosis of the two capsule leaflets to each other, thereby permanently trapping the haptic components between the capsules. During Stage 2, activation surgery may be subsequently performed to section the fused capsular bag between individual haptic components and release the restraining mechanism, thereby breaking the mechanical restraint that typically limits movement of other “in the bag” implanted IOLs.


SUMMARY

The basis for embodiments of the present invention is an accommodative-disaccommodative IOL (AD-IOL) with flexible shape shifting optic and zonular capture haptics having a dual mode of action: both an axial shift of the optic and a shape shift of the optic, driven by the dynamic balance between the action of the zonular capture haptics on the flexible optic and the shape memory of the optic and or haptic system. Embodiments of the present invention assemble together numerous individual elements, some that have been previously described separately as components of different modality IOLs, into a novel, comprehensive, and cohesive design. This unique design is specifically constructed to function in a closed and fibrosed capsular bag as is encountered after conventional cataract surgery, and results in an AD-IOL having a size similar to that of conventional IOLs. The shape shifting of the optic allows for a far greater range of accommodation than provided by the axial shift component alone. Both components act synergistically to increase the amount of accommodation obtained. The unavoidable biological response of healing and scarring after cataract surgery is not avoided, but rather utilized for the proper function of this dual mode AD IOL, which is actuated by the radial pull of the zonules. In contrast, the prior art describes attempts to prevent closure of the bag and to use the unfused capsules, open bag, to compress mechanical structures that transmit force to various optic designs, or to use the direct compression of the ciliary muscle.


The ratio between the volume and surface area of a shape shifting flexible optic changes as the optic geometry changes from accommodated to disaccommodated configuration. Embodiments of the dual mode AD-IOL described herein are adapted to alter this ratio in several ways so that the optic can attain its required degree of sphericity.


The AD-IOL enables both accommodation and disaccommodation to take place under the force load produced by zonules in the post-surgical fibrosed capsular bag, specifically as it has been measured and verified experimentally. The balance between accommodation and disaccommodation is controlled by the ciliary muscle and is transmitted via zonules, as a radial pull, to the zonular capture components of the haptic system and then to the AD-IOL system. The AD-IOL responds to the disaccommodative force exercised on it by zonules that counter the inherent accommodative elasticity of the AD-IOL, which is configured to return to a fully accommodated configuration at rest. The ciliary body contraction can then modulate the disaccommodation force exercised on the AD-IOL by zonules in a measured way under neural control, thereby allowing the AD-IOL to assume in a desired configuration based on the balance of accommodation and disaccommodation forces. The zonular capture haptics have been previously described in U.S. Patent Publication No. 2011/0307058. Embodiments of the present invention include an intraocular lens system that includes a shape-shifting flexible optic, i.e., an optic of variable power in which the power can be changed by the forces of accommodation or disaccommodation produced in the eye and that can return to the original power when these forces subside. It may also include a zonular capture haptic system. The shape-shifting flexible optic may include a small, fluid-filled, elastic thin walled optic vesicle, with characteristics adapted to be altered by action of haptics attached thereto. In use, the optic vesicle may be acted upon by the action of the haptic system during accommodation or disaccommodation. This action alters the shape of the optic vesicle thereby changing its dioptric power.


Both the optic and the haptic system may have shape memory that is calculated to generate elastic recoil of the AD-IOL to the accommodated state when zonular tension is reduced. The shape memory features of the haptic and/or optic systems cooperate to result in the ability of the AD-IOL to respond to the actual small forces generated inside the eye subsequent to cataract surgery and capsular bag closure and fibrosis.


In an aspect, embodiments of the invention relate to a dual mode accommodative-disaccommodative intraocular lens (dual mode AD-IOL) including a haptic system having a plurality of closed-loop haptics having shape memory. A shape-shifting flexible optic includes an anterior optic capsule and a posterior optic capsule, each of the two capsules having a fusion zone and the fusion zones of the two capsules being fused together, thereby defining therebetween an optic vesicle, the optic vesicle being filled with a fluid. The haptics are attached to the optic, allowing an action of the haptics to alter a shape of the optic, The shape-shifting flexible optic has a diameter of ≤8 mm. The dual mode AD-IOL, at rest, is in a fully accommodated configuration as a result of at least one of the shape memory of the haptic system and a shape-shifting capability of the flexible optic. A restraining component is sized and configured to immobilize the haptic in at least one of a flatter angle and a larger diameter in a disaccommodated configuration of the AD-IOL, when compared to the accommodated configuration.


One or more of the following features may be included. The closed-loop haptics may be at least one of trapezoidal and T-shaped. The dual-mode AD-IOL may include an optic ring that connects the haptics to each other and to the optic. The haptics may be attached to the optic by a portion of each haptic being embedded in the optic at the fusion zone. Each closed-loop haptic may be configured to adapted to transmit to the optic radial pull created by zonular tension during disaccommodation of the AD-IOL. Each closed-loop haptic may be configured to adapted to return to a set shape during accommodation of the AD-IOL.


The restraining component may be a restraining tab disposed on a haptic or an optic ring, a restraining hole defined by a haptic portion, a restraining hole defined by an optic in a fusion zone thereof, a cross bar on a haptic arm, a restraining ring, and/or a suture.


A ring-shaped plate may be embedded between an anterior optic capsule and a posterior optic capsule of the optic. The ring-shaped plate may define at least one concentric ring of holes. The ring-shaped plate may include a material having shape memory. The ring-shaped plate (i) may be more rigid than the optic and (ii) may provide structural stability to the optic. The ring-shaped plate may include a non-reflective surface.


Each of the closed-loop haptics may include a sinusoidal-shaped equatorial portion. Each of the closed-loop haptics may include a first connecting feature and the optic may include a second connecting feature adapted to engage with the first connecting feature.


The first connecting feature may be a ring defined by each of the closed-loop haptics, the second connecting feature may include a plurality of pegs defined by the optic, and each ring may be sized and configured to receive a peg.


The first connecting feature may include a T defined by each of the closed-loop haptics, and the second connecting feature may include a T-shaped groove defined by the optic and sized and configured to receive each T. Each of the closed-loop haptics may be shape set to contribute to axial shift and shape shift of the optic.


The plurality of closed-loop haptics may be defined by a continuous loop configured to change diameter in response a change of diameter of a capsular bag in which the dual-mode AD-IOL is implanted, thereby diminishing irregular tension on the optic from zonules.


Each of the closed-loop haptics may include spaced-apart ends proximate the optic, thereby enabling expansion of the closed-loop haptics.


The haptic system may include at least two optic rings, each optic ring including two closed-loop haptics, the optic rings being disposed over the optic and configured to rotate to overlay the haptics of a first optic ring over the haptics of a proximate optic ring, to reduce a profile thereof to facilitate loading of the dual-mode AD-IOL in an injector.


At least one closed-loop haptic may include a radial segment and a paddle being disposed on the radial segment configured to compress a portion of the optic.


A sum of accommodative memory of the optic and the haptic system may be accommodative at rest.


A sum of at least an accommodative memory or a disaccommodative memory of the optic and the haptic system may be less than 1 gram force. A sum of at least an accommodative memory or a disaccommodative memory of the optic and the haptic system may be less than zonular tension.


The anterior and posterior optic capsules may be fused with a bonding material and the fusion zone may define a channel configured to receive excess bonding material.


A change in a shape of the flexible optic may change a ratio of a surface area of the optic vesicle to a volume of the optic vesicle changes and the haptic system may change size and shape to accommodate the change in the ratio.


One of the optic capsules may have a thick, rigid optical zone carrying a fixed refractive power including astigmatic correction. An axis of the rigid optical zone may be marked externally. The rigid optical zone may function as a centration and fixation zone to the haptic system.


One of the optic capsules may include a thinner, more easily distorted flexion zone disposed proximate a central optical zone. One of the optic capsules may have thicker, less easily distorted piston zones disposed within or proximate to the flexion zone optic zone and adapted to push fluid toward the center of the optic vesicle. The thicker piston zone may include a plurality of structures adapted to capture and affix radial arms of the haptic system.


Each fusion zone may be adapted to embed individual haptics of the haptic system.


The optic vesicle may be filled with a constant volume of the fluid at no more than a minimally stretched configuration, to cause minimal resistance to shape shifting.


The optic vesicle may have shape memory.


The fluid may have an index of refraction greater than an index of refraction of water, e.g., substantially the same as an index of refraction of the optic vesicle.


The haptic system may be adapted to fit within an IOL injection system, e.g., adapted to roll into a cylinder.


The AD-IOL may be adapted to be restrained in a flattened, stretched out, disaccommodated configuration at implantation and during capsular bag fusion and fibrosis.


The AD-IOL may be adapted to be released by an external laser application. The external laser application may section simultaneously both the restraining device and the fused capsular bag of an eye at the same time by radial cuts between haptics, the radial cuts extending from edges of the eye's anterior capsule towards an equator of the eye's capsular bag for a distance defined to produce a desired amount of release in stiffness of the eye's fibrosed capsular bag.


In another aspect, embodiments of the invention relate to a method for implanting a dual-mode AD-IOL. The method includes providing an AD-IOL including a haptic system having a plurality of closed-loop haptics having shape memory. A shape-shifting flexible optic includes an anterior optic capsule and a posterior optic capsule, each of the two capsules having a fusion zone and the fusion zones of the two capsules being fused together, thereby defining therebetween an optic vesicle, the optic vesicle being filled with a fluid. The haptics are attached to the optic, allowing an action of the haptics to alter a shape of the optic, The shape-shifting flexible optic has a diameter of ≤8 mm. The dual mode AD-IOL, at rest, is in a fully accommodated configuration as a result of at least one of the shape memory of the haptic system and a shape-shifting capability of the flexible optic. A restraining component is sized and configured to immobilize the haptic in at least one of a flatter angle and a larger diameter in a disaccommodated configuration of the AD-IOL, when compared to the accommodated configuration. The AD-IOL is implanted into an eye of a patient. A capsular bag of the eye is allowed to fuse through the haptics. The haptics are released by making radial cuts therebetween, the radial cuts extending from edges of the eye's anterior capsule towards an equator of the eye's capsular bag for a distance defined to produce a desired amount of release in a stiffness of the eye's fibrosed capsular bag.


In one embodiment, during accommodation, the haptic arms flex closer to the axis of the AD-IOL and squeeze the optic vesicle and cause it to become more rounded, i.e., to have more convex surfaces with greater dioptric power. During disaccommodation, the same haptic arms may exert a pulling action on the optic vesicle, causing it to stretch laterally, and consequently have a less convex surface, i.e., lower dioptric power.


The optic vesicle may be manufactured from two separate components, an optic anterior capsule and an optic posterior capsule. The two are fused at their outer edges allowing the space in between to be filled with fluid. The fluid may have a higher index of refraction than water thereby conferring the biconvex optic vesicle a positive dioptric power. Ideally, the index of refraction of the fluid matched the index of refraction of the optic vesicle, thereby eliminating and optical interference from the internal surfaces of the optic vesicle.


In one embodiment, the optic vesicle is designed to be relatively small and comparable in size or volume to a standard monofocal IOL optic, with an overall disaccommodated diameter of 8 mm or less mm and optical zones of 6 mm or less, in a human sized AD-IOL. The same optic vesicle embodiment, sized for an experimental model consisting of a Rhesus monkey eyes, has an overall diameter of 6 mm and an optical zone of 4 mm.


In one embodiment, one of the optic capsules, for example the anterior capsule, has an optical zone that is thicker or more rigid such that it does not alter its shape under the forces of accommodation or disaccommodation produced in the eye. This is the prescription component of the IOL adapted to correct an individual patient refractive error. It may be shaped to confer a fixed amount of the refractive power of the IOL and also possibly an astigmatic correction power if desired. The axis of such a astigmatic correction may be marked on the edges of this thicker optical zone or structure fixing the optic.


In one embodiment the opposite capsule, for example the posterior optic capsule, remains maximally thin and flexible to allow maximum bowing or flattening under pressure or tension, from the arms of the haptic system, and thus confer an additional number of diopters during accommodation. This is the accommodative component of the optic.


In one embodiment the volume of fluid filling the optic vesicle is constant in all AD-IOLs and the curvature of the thin flexible optic zone is predictable. The variations in power required for different eyes are controlled by the fixed power of the rigid optic zone, the prescription component.


In one embodiment the optic anterior capsule and or the posterior capsule have a more rigid zone that is thicker and shaped to fit within the haptic optic ring or fusion zone or other haptic devices for secure centration. In other embodiments, ridges, protuberances or other structures ensure centration in the optic ring or other haptic devices.


In one embodiment the optic anterior or posterior capsule has a thinner, maximally flexible zone that corresponds to the haptic flexion zone, and allows a change in the shape of the optic vesicle with minimum resistance. This flexion zone is peripheral to the optic zone. In another embodiment the flexion zone has external pegs for direct attachment of haptic proximal ends.


In one embodiment the optic anterior or posterior capsule has thicker zones, blocks with grooves to incorporate and fix the haptic radial arms. Additional thicker and more rigid zone may exist in between haptics. The overall rigidity of this zone allows it to also function as a piston zone, driving fluid centrally to cause a bowing of the thinner capsule optical zones. This zone is peripheral to the flexion zone.


In one embodiment, the haptic arms have wide plate like structures adapted to press on the optic flexion zones.


In one embodiment, the outermost zone of the optic anterior capsule, on its underside, has a fusion zone designed to become fused to a corresponding zone on the posterior capsule of the optic vesicle. Channels or groves allow excess bonding material to pool at the fusion zone and not spread out. One or more fluid filling channels may be built into the thicker blocks zone or other suitable locations.


In one embodiment, columns or ridges or ribs are built internally between the anterior and posterior capsule to diminish movement of the more rigid prescription zone during accommodation. Such structure have the added benefit of adding structural stability to the shape of a flexible optic and limit distortion.


In one embodiment the optic vesicle is filled with fluid to the full non-stretch or minimally stretched volume, where the capsules of the optic vesicles are shaped set for a disaccommodated configuration. The accommodative elastic force of the AD-IOL is provided primarily by the haptic system.


In one embodiment the optic vesicle is constructed separately and independently from the haptic system and the two are assembled together by pressing the optic vesicle into the haptic structure. The optic vesicle can be snapped into and secured to the haptic system by precise geometry and mechanical snug fit, or parts of it may be incorporated into the fusion zones, or it may be additionally secured after assembly with additional polymer or adhesive added to the grooves containing haptic arms or other haptic attaching components.


In one embodiment, the haptic system is maintained disaccommodated after IOL implantation with a loop, or a ring of polypropylene or other similar biocompatible materials, that can be transacted and rendered inoperative by the use of a laser, for example a YAG or femtosecond laser, or surgical instruments. Such loop may be fixated to positions of AD-IOL, so that if the restraining loop is cut, the segments of the loop remain attached to the AD-IOL outside of the optical zone, and need not be removed from the eye.


In one embodiment the optic may incorporate an artificial iris element that blocks the passage of light through the peripheral zone of the optic from being transmitted to the inside of the eye. The peripheral zone undergoes purposeful mechanical alterations that reshape the central optical zone, but in themselves can cause undesirable image distortions and artifacts.


In one embodiment, the optic may incorporate a mechanical reinforcement element, that stabilizes the shape of the optic vesicle and may have shape memory or superelasticity.


In one embodiment, the optic vesicle may have an integrated haptic restraining component that is separate from the haptic system.


In yet another embodiment, the incorporated artificial iris, reinforcing element, and the haptic restraining element may coexist in a single element, and this element may have a non-reflective surface.


In one embodiment, the haptic system may be adapted to be rolled into a narrow cylinder to facilitate its injection into the capsular bag at the time of surgery. Such adaptations may include, but not be limited to altering the number of haptic arms, altering the connections between the haptic arms, altering the shapes or sizes of loops that allow the eye's anterior and posterior capsule to fuse through and thus fixated the haptics, and any other feature known to one of skill in the art.


In another embodiment, two or more optic rings with two haptics each are superimposed and can rotate about the optic. Before loading the AD-IOL in an injector, the top ring or rings are rotated so that their haptics overlay the bottom ring, in effect forming a two-haptic AD-IOL for the purpose of limiting injector size. Once implanted into the eye, the surgeon rotates the top ring or rings so that all four or more haptics are uniformly distributed in the capsular bag.


In certain embodiments, the optic vesicle, restraining ring, and haptics may each include a biocompatible plastic, such as polypropylene, poly(methyl methacrylate), polyamide, nylon, polyester, polyvinylidene fluoride, and/or silicone. The haptics and optic securing components and restraining components may each include a biocompatible metal or alloy, such as stainless steel and/or nickel titanium alloy.


In one embodiment, the optic vesicle is filled with a biocompatible fluid with an index of refraction greater than water, such as but not limited to silicone oil.


In another embodiment of the invention, the optic vesicle is filled to a non-stretch or minimally stretched volume and shape set for accommodated configuration. In this embodiment, the action of zonular capture haptics is primarily to stretch the optic vesicle to its disaccommodated, flatter shape. The elastic accommodative force is contained primarily in the fluid-filled vesicle, not in the haptic structure.


In this embodiment, the AD-IOL is implanted in a stretched disaccommodated configuration, by the action of a restraining device.


In another embodiment, the elastic accommodative force is contained in the shape memory of both the fluid-filled vesicle and in the haptic structure, and their elastic recoil may be additive or subtractive to result to an overall level that can be disaccommodated by zonular tension, at about 1 gram of force or less per individual haptic.


In another embodiment, the optic vesicle can alter its surface area to volume ratio as it changes from accommodated to disaccommodated state to conform to the required geometry by stretching or un-stretching the optic flexible zone or by pumping in or drawing our fluid under the action of the haptics.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B are perspective views of a dual mode AD-IOL in disaccommodated (FIG. 1A) and accommodated (FIG. 1B) positions, illustrating both the axial shift and the shape shift of the optic with accommodation, in accordance with an embodiment of the invention;



FIG. 2 is a schematic diagram of a top view of an optic vesicle in accordance with an embodiment of the invention superimposed on a photograph of a prior art haptic system, maintained in fully disaccommodated position by a surgical forceps, constructed out of nitinol and sized for a Rhesus monkey eye;



FIGS. 3A, 3B, 3C, and 3D are schematic diagrams of optic anterior and posterior capsules, specifically anterior top view (FIG. 3A), cross-section (FIG. 3B), posterior from above (FIG. 3C), and in cross-section (FIG. 3D), in accordance with an embodiment of the invention;



FIG. 4 is a schematic view of optic anterior and posterior capsules in cross-section, after having been fused and the optic vesicle has been filled with fluid in accordance with an embodiment of the invention;



FIGS. 5A and 5B are CAD-generated images of a fully assembled dual mode AD-IOL in a perspective view (FIG. 5A) and in partial cross-section (FIG. 5B), revealing the interaction of the optic vesicle with the haptic system, in accordance with an embodiment of the invention;



FIG. 6A is a schematic view of a haptic structure in accordance with an embodiment of the invention, including some modifications to allow rolling of the AD-IOL into a tight cylinder, to facilitate implantation by injection into the eye through a small incision; FIGS. 6B and 6C show an embodiment of the invention in which two optic rings with two haptics are overlaid and can rotate about the optic, so that prior to loading in the injector, the top ring is rotated with its haptics overlaying the haptics of the bottom ring. Once implanted in the eye, the surgeon rotates the top optic ring by 90 degrees, restoring the four-haptic configuration.



FIGS. 7A and 7B are CAD-generated images of an optic vesicle shaped and filled to the accommodated fill volume, the zonular capture haptics being independent of each other and function primarily by stretching the optic vesicle during disaccommodation, in accordance with embodiments of the invention. FIG. 7A depicts an assembled AD-IOL with a restraining ring above it and FIG. 7B is an exploded view of the components;



FIGS. 8A and 8B show the AD-IOL of FIGS. 7A and 7B in cross-section, in the shifted disaccommodated position (FIG. 8A) and in resting accommodated configuration (FIG. 8B). The AD-IOL has a larger diameter, and a thinner and less curved optic vesicle in the disaccommodated position;



FIG. 9 illustrates an AD-IOL similar to the AD-IOL of FIG. 7, but with the haptics connected by a continuous ring, adapted to respond to a reduction in the diameter of the eye's capsular bag during accommodation, in accordance with an embodiment of the invention. In this embodiment, both the haptic structure and the optic vesicle contribute to the elastic force needed to accommodate the AD-IOL;



FIG. 10 illustrates a finite element analysis of the optic properties of the AD-IOL depicted in FIG. 9, showing an aberration-free optical zone in the center of the optic vesicle;



FIGS. 11A and 11B are photographs of a nitinol restraining ring (FIG. 11A), and the nitinol restraining ring in position disaccommodating the AD-IOL (FIG. 11B), in accordance with embodiments of the invention;



FIGS. 12A, 12B, and 12C are CAD-generated images of a section of a dual mode AD-IOL in accordance with an embodiment of the invention, in a perspective view (FIG. 12A) cross-section view (FIG. 12B), and perspective view of the entire AD-IOL (FIG. 12C). In this embodiment, the haptics exert radial pull directly on the thin anterior capsule of the optic, which represents the accommodating component of the optic. The posterior capsule is rigid and conveys the prescription optical power;



FIG. 13 is a schematic drawing of a configuration for a continuous nitinol wire haptic adapted to work with the dual mode AD-IOL of FIG. 12C and; and



FIG. 14 is a CAD-generated image of a section through a dual mode AD-IOL in accordance with embodiments of the invention, in which paddle-like structures on the arms of the haptics press on thin zones of the optic vesicle to direct the fluid to the anterior optical surface, which provided increased power during accommodation. The posterior optical surface is more rigid and conveys the prescription refractive power.





DETAILED DESCRIPTION

All patent applications, patents, and other references cited herein are hereby incorporated by reference in their entirety into the present disclosure.


In ophthalmology, the term “haptic” refers to a structure that extends out from an optic element of an intraocular lens, usually for holding the lens in place within the capsular bag of the eye. Herein, “haptics” are sometimes referred to as “zonular capture haptics,” or collectively as a “zonular capture haptic system,” or simply “haptic system” and refer to structures or material that not only assist with placement and centration of the lens within the capsular bag to transmit zonular movement to the lens, but also permit secure fixation in between or to the anterior or posterior capsule following removal of the natural lens and placement of the artificial lens. A haptic system may also include an optic retainer for holding an optic. An “optic retainer” is a portion of the haptic system that holds the optic, e.g., a ring, pins, or other attachment mechanism.



FIGS. 1A and 1B depict one embodiment of a dual mode accommodating-disaccommodating IOL with zonular capture haptics 100 coupled to a both axial and shape-shifting flexible optic 105. The zonular capture haptics 100 have been previously described in U.S. Pat. No. 9,364,318, incorporated herein by reference in its entirety. The zonular capture haptics 100 include a flexion zone 110, a radial arm 115, and a capsular bag capture zone 120 that has a sinusoidal indentation 125 that allows the circumference to change simultaneously with the equator of the capsular bag. Each individual haptic 100 has a T-shaped, closed loop configuration that allows contact and fusion of the anterior and posterior capsules of the eye through and around the closed loops. The plurality of haptics 100 defines a disc that is coexistent with the fused capsular bag. The equatorial zones of the haptics 100 are generally circumferential with the capsular bag equator and provide the main anchoring zone of the fused bag to the haptic system; hence they represent the zonular capture zone. Restraining tabs 130 protrude horizontally and radially out of the optic ring 135 between haptics 100 or, alternatively, on both sides of each haptic arm 115. They extend in length past the length of the flexion zone 110 and they are constructed to be relatively rigid in comparison to the flexion zone of the haptic arms 115. The haptics 100 are shaped set to be in an accommodated configuration at rest, and can be restrained by securing them to restraining tabs 130 into a flat disaccommodated configuration with a biocompatible suture or other similar devices. The haptics 100 are preferably constructed from nitinol, as thin as 0.001″-0.002″ and can be disaccommodated by zonular tension exerted via the fused capsular bag at about 1 or less gram of force on each haptic 100.


The zonular capture haptics 100 are connected to each other and the optic 105 by an optic ring 135, which may be a single continuous structure or may be made of multiple segments or elements designed to hold the optic 105. The optic ring 135 or optic ring segments may attach to the optic 105 by a snug fit to parts of the optic 105, by being fused to the outside of the optic 105, or by being contained in part or in whole inside the fusion zone of the optic 105 or other parts of the optic 105 adapted for this purpose.


In FIG. 1A, the IOL is shown in a flattened, disaccommodated position and the disaccommodated optic thickness is highlighted by the double arrow 140. In the accommodated position in FIG. 1B, the lens thickness increases by an additional amount, depicted by the double arrow 145 and the optic shifts axially by vaulting anteriorly in the eye by an amount depicted by the double arrow 150.


In use, restraining tabs 130 are utilized to lock the haptic structure at implantation and for some weeks afterwards in a disaccommmodated configuration, until such a time that the capsular bag fusion and fibrosis has completed. The haptic arms 115 are maintained in a horizontal position by virtue of a loop of biocompatible material, such as a suture woven under haptic arms 115 and over restraining tabs 130, or a ring 155 such as the one in FIGS. 11 A and 11B. The haptics 100 allow room for radial sections in the fused capsular bag from the edge of the anterior surgical capsulotomy towards the equator of the bag. The length of these radial cuts can be adjusted to the amount of capsular bag fibrosis restriction release necessary and can be performed non-invasively with a YAG or femtosecond laser. During accommodation, the haptics 100 flex posteriorly and squeeze the optic vesicle into a more spherical shape. During the disaccommodation, they stretch it to a less spherical shape.


Referring to FIG. 2, the shape shifting optic 105 includes a fluid-filled vesicle. The optic vesicle is depicted superimposed on a photograph of a haptic system in accordance with the prior art, to illustrate the relationship between the two structures. Both are sized for a Rhesus monkey eye. The haptic system, constructed out of nitinol is maintained in a fully disaccommodated position by a surgical forceps. The optic 100 has a thinner flexion zone 160, generally situated under the haptic flexion zone 110 and peripheral to the central optic zone 165. The peripheral part 170 of the flexion zone 110 may be thicker and function as a piston zone; the peripheral part 170 may have more rigid components, shaped as blocks 175 to retain and fix the distal part of the haptic arms 115.



FIGS. 3A, 3B, 3C, and 3D are diagrams of the components of the shape shifting optic 105 shown in FIG. 2, specifically anterior top view (FIG. 3A) and cross-section (FIG. 3B), posterior from above (FIG. 3C), and in cross-section (FIG. 3D). The optic has an optic anterior capsule 180 and an optic posterior capsule 185.


In one embodiment the optic anterior capsule 180 has a central optical zone 165 that is thicker, more rigid and fits snugly inside of the optic ring of the haptic structure. Such optical surface may provide a predetermined customizable power for the IOL that is specific for each patient, for example 15 D vs. 16.5 diopters, and may have an astigmatic correction component as well, if so desired. This is the prescription component of the IOL. The axis of this surface is marked on the edges of the optic zone or the haptic structures holding the optic 105 in place. In one iteration, the greater thickness of the fixed optical surface, for example 200-500 microns, is elected to make it sufficiently rigid as to not be altered in the shape by the actions of the haptics 100 or shifting fluid. Immediately peripheral to the optical zone 165, a thinner flexion zone 160, generally situated under the haptic flexion zone 110, facilitates a shape change for the optic 105 under the squeezing or pulling effect of the radial haptic arms 115 during accommodation. The flexion zone 160 may be as thin as 25-50 microns. The peripheral aspect of the flexion zone 160 may be more rigid 170 and function as a piston zone and has more rigid components, shaped as blocks 175 to retain and fix the distal part of the haptic arms 115. The haptic arms 115 may fit snugly, e.g., snap in, in the grooves or notches within or in between these blocks and may be additionally secured with a biocompatible polymer or adhesive when the lens is assembled. The outermost edge of the optic anterior capsule, on the underside of the structure, is designed as a fusion zone 190 to the corresponding fusion zone of the optic posterior capsule 195.


In addition to securing the optic to the haptic radial arms, so that the optic vesicle can be both compressed and stretched by the flexion and extension of the haptic arms, such rigid sections also function as piston zones, forcing the fluid displaced by compression during accommodation toward the center of the optic vesicle. Additional piston zones may be placed between haptics as needed.


In one embodiment, the optic posterior capsule 185 is thin, e.g., having a thickness of 25 microns to 50 microns for example, and fused on its outer most edge 195 to the optic anterior capsule. The central portion of the optic posterior capsule is the optical zone 200 and may or may not have an additional molded refractive shape and it represents a variable power optical zone, the accommodating component of the IOL.


Referring to FIG. 4, the components illustrated in FIGS. 3A-3D may be assembled to form a shape-shifting optic 105. A space 205 between the anterior and posterior capsules is filled by a biocompatible fluid with an index of refraction higher than that of water, such as, for example, silicone oil. Ideally, the fluid has the same index of refraction as the material in the optic vesicle, thereby reducing any internal optical interferences. When the optic vesicle is filled with fluid, the thin posterior capsule assumes a convex configuration, creating a positive refractive surface.


During accommodation, when the haptic arms 115 flex toward the axis of the IOL, fluid in the optic 105 is displaced centrally by the piston zones of the optic anterior capsule, resulting in additional bowing of the optic posterior capsule and an increase in its refractive power. The optic posterior capsule in this embodiment is sufficiently thin to undergo shape shifting with minimal resistance to the haptic arms 115. In another embodiment, the thicker, fixed optical zone may be placed on the optic posterior capsule and the variable optical zone on the optic anterior capsule. In such an embodiment, additional pegs or ridges or other fixation structure (not shown) may be built on the optic anterior capsule to allow its centration on the haptic optic ring 135.


In another embodiment, the entire optic 110 is manufactured in a rotational mold machine that creates a single vesicle at once and eliminates the need to fuse separately molded capsules.


Referring to FIGS. 5A and 5B, an exemplary combination of a haptic system with an optic vesicle is illustrated. The CAD generated images show a perspective view (5A) and cross-section (5B) of a dual mode AD-IOL with the prescription component on the rigid anterior capsule 165 and the variable accommodating component on the thin posterior capsule 200; the relationship between the haptic flexion zones 110 and the optic flexion zones 160 is illustrated as well. The flexion of the haptics 110 during accommodation drives fluid centrally to force the accommodative component to become more spherical. The extension of the haptics 100 during disaccommodation drives fluid peripherally to cause the accommodating component to become less spherical. The shape memory of the optic 105 and the haptic systems is configured to provide, in sum, an accommodative elastic force smaller than the disaccommodating force generated by the eye, so that the movement of the AD-IOL can be controlled by the action of the ciliary muscle. For example, the haptic system may be shape set for an accommodated configuration while the optic 105 is shape set for a disaccommodated configuration, or vice versa, or both the haptic system and optic 105 may be set for accommodated configuration. The exact combination is determined by the dimensions and the material properties of the haptic and optic systems.


Referring to FIG. 6A, in one embodiment, the haptic system may be adapted to be rolled into a narrow cylinder to facilitate its injection into the capsular bag at the time of surgery. Such adaptations may include, but not be limited to altering the optic ring 135, the flexion zones 110, and/or the number of haptic arms 115, altering the connections between the haptic arms 115, altering the shapes or sizes of loops of haptics 100 that allow the eye's anterior and posterior capsules to fuse through and thus fixate the haptics 100, and any other suitable feature known to one of skill in the art. In the illustrated embodiment, the closed loops of the haptics 100 at the end of each haptic arm 115 have a reduced diameter proportionate in size to the inner diameter of the injection tube, so that they can pass through the tube without being crimped into a permanently distorted shape. For the same reasons, the haptics arms 115 are narrow and oriented such so that they can be rolled over the optic 105 into the injection tube along the 6-12 o'clock axis, for example. Rolling the haptic arms 115 over the rolled optic 105 prevents a sharp bend in the material that may lead to crimping or permanent disfiguration of the haptics 100.



FIGS. 6B and 6C show an embodiment where two optic rings 135′ and 135″, having two haptics 100 each, are overlaid and can rotate about the optic 105. Prior to loading in the injector, the top optic ring 135′ is rotated with its haptic arms 115 overlaying the haptic arms 115 of the bottom optic ring 135″, in effect presenting only two haptics 100, 180 degrees apart, to the injector. Once implanted in the eye, the surgeon may rotate the top optic ring 135′ by 90 degrees, restoring the four-haptic configuration. Alternatively, multiple optic rings 135 can be overlaid for haptic configurations with more than four haptics 100. The greater the number of haptics 100, the more uniform is the transmission of zonular forces to the optic 105 and the better the control the capsular bag geometry through the fibrosing phase but the complexity of the design of the IOL and the injector is greater and the implantation is more difficult. The minimum number of haptics 100 to achieve the right balance, possibly three to four, can only be determined by the specific materials and dimensions used for any iteration. The bottom optic ring 135″ contains the diasaccommodative restraining device (not shown). In FIG. 6A the haptics 100 are nearly completely overlapped, in FIG. 6B they are in the desired configuration.


In one embodiment, the volume of fluid inside the IOL is calculated to be constant fill, to a non-stretch or minimally stretched vesicle volume. This allows shape shifting of the vesicle with minimal resistance. The fill of the optic vesicle bows out the variable power zone, the accommodating component, on the optic posterior capsule, for example, to a predetermined and fixed power for each corresponding haptic configuration. This power added to the power of the rigid optical zone, the prescription component, on the opposite capsule constitutes the IOL power for that particular haptic configuration, for distance or disaccommodated vision. Additional power is obtained during accommodation by the compression caused by the flexion of the haptics 100, elastic recoil of the optic vesicle, or both, which bows the optic posterior capsule further and, in doing so, increasing its power by up to 14 diopters. One or more filling channels can be constructed within the thicker regions of the optic vesicle such as the pistons blocks or haptic retaining blocs, or any other suitable locations. These channels are utilized to fill the optic vesicle with fluid and remove any inadvertent air bubbles during assembly.


Referring to FIGS. 7A, 7B, 8A, and 8B, in another embodiment, the elastic optic vesicle is shape set for an accommodated configuration at rest. In FIG. 7A the device is assembled, including a restraining ring 155, with FIG. 7B being an exploded view with individual components. The same device is shown in cross-section in shifted disaccommodated configuration (FIG. 8A) and resting accommodated configuration (FIG. 8B). In these instance, the haptics 100 act by stretching the optic in disaccommodation.


The zonular capture haptics 100′ may be separate as in FIGS. 7A, 7B, 8A, and 8B. Referring to FIGS. 9 and 10, alternatively, the zonular capture haptics may be in the form of a continuous ring 220. The haptics are embedded in the fusion zone between the anterior and posterior capsules. The haptics are able to receive a restraining device in openings or notches 215. In FIGS. 7A, 7B, 8A, and 8B, the haptic segments trapped within the fusion zone define, for example, two rings each. The openings inside these rings represent restraining holes 215 and generally match in size the corresponding restraining holes 210 in the restraining ring 155. These holes may be, for example, 100-500 microns in diameter, and may be covered on both sides by the silicone layer of the fusion zone, or the opening may extend through the entire fusion zone. The exact number and dimensions of the restraining holes is determined by mechanical and thermal properties of the restraining sutures or pegs and the mechanical load exerted on them. The smaller the number and dimensions of the sutures or pegs, the safer and easier it is to release them with an external laser, provided that the restraining is stable, reliable through implantation and after, and the geometry of the locked AD-IOL is adequate.


Referring to FIGS. 7A, 7B, 11A, and 11B, the IOL may be implanted with a restraining device 155 such as a ring that has corresponding restraining holes 210 or pegs adapted to couple with the haptic restraining holes 215 to keep the optic 105 stretched or shape-shifted to the fully disaccommodated diameter. The corresponding restraining holes in the optic 105 are affixed to the holes 210 in the restraining ring 155 by a suture or a peg of biocompatible material that can preferably be cut or melted or reduced in size to break the bond, by external laser application, or with surgical instruments. The stretch of the elastic optic vesicle resists deformation during disaccommodation and returns the optic vesicle to the less stretched configuration when haptics 100 stop pulling on it. Both anterior and posterior optical zones are variable but their thickness profiles may or may not be symmetrical or uniform. The sum of their refractive powers in a disaccommodated state constitutes the prescription power, while the sum of their powers in an accommodated state represents the near vision correction for the patient. The uniform distribution of the multitude of haptics attachment points about the optic allows uniform distribution of forces on the optic 105 and leads to a distortion free optical zone, zone as seen in the Finite Element Analysis software generated diagram in FIG. 10. If a continuous haptic 220 is used, this further diminishes the risk that irregular contraction of the capsular bag may cause irregular optic distortion. The continuous haptic 220 is generally sinusoidal shaped to allow for a change in diameter in sync with the change in diameter of the fused capsular bag. A continuous haptic 220 may be shape set to contribute to either the accommodative or diasaccommodative effort by a variance of its overall diameter, variance of an axial shift, or both.


After implantation, the ring 155 may be deactivated by cutting it in sections with an external, non-invasive laser or with surgical instruments, or disconnecting it from the IOL, and it may or may not need to be removed from the eye, based on multiple possible configurations.


The restraining ring 155 may, as seen in FIGS. 11A and 11B, have thinner zones 225 to facilitate cutting the ring 155, thicker zones 230 to optimize the restrained position of the haptics 100, and tabs 235 to facilitate its centration. The restraining ring 155 may rest passively on the AD-IOL, or may be fixed in place.


The restraining ring may 155 be cut simultaneously with radial cuts in the fused capsular bag of the eye, between haptic elements. Such cuts may extend from the edge of the anterior capsulotomy surgically performed in the eye's anterior capsule at the time of surgical implantation, towards the equator of the eye's capsular bag, for a predetermined distance measured to cause a sufficient release in the stiffness of the eye's fibrosed capsular bag to obtain the desired amount of movement of the AD-IOL of embodiments of the invention.



FIGS. 12A and 12B show perspective and cross-sectional CAD-generated views of a section of a dual mode AD-IOL, and FIG. 12C shows the entire dual mode AD-IOL in perspective view. In this illustrated embodiment, the accommodative component is made of a very thin anterior capsule 180 that can be as thin as 25-50 microns and built of shape memory silicone elastomer. The anterior capsule 180 may have a total diameter selected from a range of 6 to 8 mm, when in a disaccommodated position. A central optical zone 165 of the anterior capsule 180 may have a diameter selected from a range of 4 to 6 mm. Ideally the design aims for the largest optical zone afforded by the smallest diameter of the entire optic 105.


Immediately peripheral to the central optical zone 165 of the anterior capsule 180 is a flexion zone 160 of the optic 105, which includes protruding pegs 240 for attachment to haptic attachment rings 245 (described below). The pegs 240 may be circular or non-circular in shape, may protrude at a direction parallel to the visual axis, or a different direction, may have a wider base to support the haptic attachment rings, and may have a wider mushroom like cap to prevent the pegs 240 from being dislodged under tension. In an embodiment, the pegs 240 are cylindrical with a diameter of 100-500 microns and a height of 200-500 microns, with one peg 240 per haptic attachment point, preferably 6 pegs or more, preferably 8. The overall number and dimensions of the restraining pegs 240 are governed by the mechanical properties and dimension of the optic and haptic components balanced against design and usage limitations. The greater the number of pegs 240, the more uniform the zonular tension that is applied to the optic 105, the lower the mechanical load on each peg 240, and the greater the complexity of the AD-IOL construction and usage. Alternatively, the geometry of the connection between the proximal end of the haptic 100 and the flexible optic 105 may have an alternative geometry, such as a T or anchor-shaped haptic end in a matching groove, or other configurations known in the art.


The region of the flexion zone 160 between pegs 240 may be thicker and may be sinusoidal in configuration, continuously or in separate segments, to distribute the pulling vectors on the optical zone more uniformly and over a broader zone of the optical zone, without hindering the ability of the flexion 160 and optical zone to expand to a wider diameter during disaccommodation. In an exemplary embodiment, the flexion zone 160 may have a thickness selected from a range of 25 to 50 microns, and a width selected from a range of 200 to 500 microns.


Peripheral to the flexion zone 160 is a fusion zone 290 of the anterior optic, where the anterior optic is fused to a fusion zone 195 of the posterior optic 185. The fusion zone 290 of the anterior optic may have a width selected from a range of 100 to 1000 microns. An overhanging lip 250 disposed on the outer periphery of the anterior optic fusion zone, or alternatively on the posterior one, allows for better centration and a more secure seal when the elements are assembled. This anterior optic component provides the presbyopic correction.


The posterior optic element 185 is substantially thicker, to resist distortion, and carries the prescription refractive power, the power that corrects the individual patient's aphakic refraction. A thickness of the posterior optic element 185 may be selected from a range of 100 to 500 microns. The posterior optic element 195 has a posterior optic fusion zone, with a width selected from a range of 100 to 1000 microns. Generally the smallest dimension that allows the prescription optical zone to resist flexion during accommodation is preferable, as it reduces the overall bulk of the AD-IOL.


A ring-shaped plate 255 made of shape memory metal, such as nitinol, is embedded between the anterior and posterior optic fusion zones. The plate 255 extends from the outer edge of the optical zone towards to periphery and up to the overhanging lip in the fusion zone, being completely enclosed within the fused silicone capsules. The area of the plate 255 under the flexion zone 160 is solid, while the area within the fusion zone 290 is perforated by one or more concentric rings of holes, with each having a diameter of, e.g., 100 to 500 microns. The holes are preferably spaced 50 to 200 microns apart, to facilitate the use of a suture, as described below. The plate 255 may be 0.001 to 0.002″ in thickness. The surface of the plate 255 may be treated to be dark, or non-reflective, by means of laser surface modification, or chemical or pigment deposition. The dark or non-reflective surface reduces light scatter inside the eye, which may cause image degradation, patient discomfort, and/or a cosmetically objectionable mirror-like surface in the pupil of the patient when the patient's pupil is dilated, for example in a low light environment. A similar treatment, for the same reasons, may be applied to the optic ring and haptics.


In an embodiment, the ring-shaped plate 255 has three separate functions. A pericentric zone 260, located underneath the flexion zone 160 of the anterior capsule functions as an artificial iris to block peripheral stray light and prevent image distortion and degradation through the flexion and fusion zones of the optic 105. The size of the hole in the center of the ring-shaped plate 255 becomes an effective pupil, allowing only light traveling through the optical zones of the optic 105 to reach the patient's retina. The size of the hole preferably generally matches the diameter of the optical zones and may be, for example, 4 to 7 mm in diameter, to allow the maximum amount of non-distorted light to pass through to the retina.


Immediately peripheral to the pericentric zone 260 is disposed a restraining zone 265 that defines one or more rings of concentric restraining holes 270 sized and distributed to facilitate restraining the haptic in a disaccommodated position at implantation and several weeks thereafter, described below. Accordingly, the restraining holes 270 extend through the anterior capsule, holes defined in the ring-shaped plate 255, and the posterior capsule, or may be completely covered by a continuous layer of silicone elastomer. The restraining holes 270 preferably have a diameter of 100 to 500 microns, and are spaced 50 to 200 microns apart. Preferably, at least 2-4 holes are disposed in a vicinity of each peg 240. The ideal number and size of the restraining holes 270 have been discussed above. The remainder of the holes 270, not in position to restrain the haptic arms 115, are generally larger to allow for more adhesive contact between the fusion zones of the anterior and posterior optic while maintaining structural integrity of the plate 255 and not allowing too much stray light to travel to the back of the eye.


The haptics 100 in this embodiment are zonular capture haptics made of shape memory metal, such as nitinol, and can be as thin as 0.002″. The arms of the haptics 115 move in the same plane with the fusion zone, which corresponds to the plane of axial pull by zonules in the closed and fused capsular bag. The individual haptics 100 allow room for radial capsular sectioning between the haptics 100. The flexion zone of the haptic 110 is short and at a relatively steep angle to allow the haptic peg rings 245 to approach the optic pegs 240 for fixation. The optic peg rings may be circular or a different shape, generally matching the shape of the pegs 240, and sized to make a tight fit or squeeze on the pegs 240. Cross bars 275 on the haptic arms 115 allow restraining of the haptics 100 to a disaccommodated configuration by suturing across the optic fusion zone, through the restraining holes, as described below. In addition to the restraining function, the holes allow direct contact between the anterior and posterior capsules and with bonding material to form a more secure fusion of the anterior and posterior optics. The short and steep flexion zones 110 of the haptic 100 convert most of the radial zonular pull into a shape shifting effect on the optic 105 with a smaller effect towards an axial shift of the optic 105. The distal portion of each haptic 100 has a sinusoidal shape 125 to allow this end of the haptic 100 to expand and contract circumferentially and in step with the change in diameter of the capsular bag during accommodation and disaccommodation, so that the haptic 100 does not impede the movement of the fused capsular bag. For a similar reason, the two proximal ends of each haptic 100, attached to the pegs of the optic 105, are not connected to each other. Rather, the proximal haptic ends form an open loop, so that the pegs and haptic ends can move to a larger diameter when the anterior capsule stretches during disaccommodation. The haptic 100 is shape set for the accommodated configuration.


In use, a suture is passed across the fused, silicone peripheral capsules, through the restraining holes, and around each cross bar 275 on the arm of the haptic 115 to create a loop to immobilize the haptic 100 in stretched disaccommodated position. The suture may be made from any biocompatible material known in the art. Such a suture may be cut by non-invasive external laser application, such as YAG or femtosecond laser. The cut suture segments may be trapped in the silicone fusion zone and may not necessarily be removed from the eye. Once the suture is cut, the haptic 100 is free to move.


The third purpose of the embedded plate 255 is to enhance the structural stability and shape memory of the flexible silicone optic, to ensure that it returns to a desired shape after compression or deformation during the implantation step, for example by being forced to go through a small incision injector. Similarly, an optic 105 sufficiently thin to be shape shifted by weak zonular forces has some preferred areas of stable geometry during haptic movement, to direct all movement energy to the accommodating element and not the reminder of the flexible optic.


In the embodiment illustrated in FIGS. 12A-12C, during disaccommodation, the radial pull of the zonules is converted mostly to a radial pull of the haptics, which is conveyed to the pegs on the flexion zone of the optic. This radial pull flattens the optical zone to reduce its optical power by increasing the diameter of the optical zone. The optic is filled with a fluid having a high index of refraction fluid, as silicone oil, in a resting accommodated shape. A preferred index of refraction of the fluid is, e.g., at least 1.30 to 1.55. The greater the refractive index, the more accommodative power is provided for a smaller change in shape. However, this may result in greater viscosity which could make movement more difficult, or in a chemical composition which may not be compatible with the optic vesicle polymer over several decades. Since the volume of fluid in the optic vesicle is constant, the anterior capsule will stretch to increase its surface area, to reach the volume/surface area ratio required by the geometry of a flatter optic. The anterior capsule is very thin to allow for this stretch to occur below the disaccommodative load level that can be generated by the eye. When ciliary body contraction neutralizes the radial pull of the zonules, the shape memory of both the optic and the haptic reshape the optic to a more convex shape and a more anterior location, thereby increasing its power, by as much as 10-15 diopters.


The AD-IOL is manufactured from four separate components that are assembled together. The two optics elements (anterior and posterior capsules) are molded as individual components from silicone elastomer or a similar biocompatible material. The individual haptics and the ring plate are laser cut from a nitinol sheet of desired thickness, which can be as thin as 0.002-0.001 inches. The haptic is heat shaped to its accommodated configuration. The surface of the nitinol parts is chemically treated to increase biocompatibility and remove any laser-induced irregularities, for example by a chemical or electrochemical pickling or oxidizing bath or other processes known in the art. The ring plate is positioned in place in the posterior optic element with a bonding material in the fusion zone, such as uncured silicone elastomer or silicone adhesive. Additional bonding agent is added and the anterior capsule is added with the overhanging lip covering the seam between the ring plate and the posterior optic capsule. The three components are clamped and heat treated to cure the bonding material. A needle enters the optic tangentially through the fusion zone, and silicone oil is injected into the central cavity; any air bubbles are meticulously removed. The silicone fill is adjusted to achieve the desired optical power with minimal or no stretching of the thin anterior capsule. When the needle is removed, the external ostium of the self-sealing needle passage is further sealed with bonding material. The haptic is placed in position by grasping the optic pegs and pulling them through the corresponding holes in the haptics. Additional bonding material is applied as a mushroom cap to the pegs, or the optic rings can be secured with miniature rivets, sutures, or other devices know in the art. Alternatively, the optic vesicle is manufactured as a single piece by rotation molding or a similar technique and the ring plate is fused externally to either the posterior or anterior fusion zone.


An alternative haptic configuration uses a continuously looped nitinol wire, with loops capturing the attachment optic pegs, restraining holes and equator of the capsular bag in patterns similar to intravascular stents. This continuous loop haptic makes contact with more points in the equator of the fused capsular bag and distributes uneven lateral loads throughout the haptic system to decrease the risk of optical distortion of the very thin anterior capsule. In particular, referring to FIG. 13, a continuous loop nitinol wire haptic 220 may be adapted to work with the dual mode AD-IOL of FIG. 12C. The haptic has loops 245 to capture the optic pegs 240, openings or notches 215 for receiving a restraining device proximate the fusion zone of the optic 105 and a sinusoidal equatorial region 125 adapted to change diameter in synchrony with the capsular bag. The haptic is shape set to cooperate with the elastic recoil of the flexible optic and allow for accommodation and disaccommodation to take place under the force load produced in the eye. The continuous loop of the haptic allows for uniform distribution of lateral or irregular circumferential stresses on the haptic, as they may occur after capsular bag closure and fibrosis, and such to minimize irregular distortion of the flexible optic.



FIG. 14 is a CAD-generated image of a section through an alternative dual mode AD-IOL. This embodiment utilizes a flexible optic made from an anterior 180 and a posterior 185 capsule fused together and a haptic system configuration, essentially similar to the one in FIG. 5. This haptic configuration has been proven to capture the movement amplitude and dynamics in the eyes of a Rhesus monkey experimental model over extended periods of time, in a fibrosed and fused capsular bag, and to convert that movement into a maximal axial shift.


The haptic system includes an optic ring 135, radially extending restraining tabs 130 and radially extending closed looped haptics. Each haptic 100 has an equatorial region 120 that becomes captured in the fused capsular bag, and has a generally sinusoidal shape 125 to allow this end of the haptic 100 to expand and contract circumferentially and in step with the change in diameter of the capsular bag during accommodation and disaccommodation, so that the haptic 100 does not impede the movement of the fused capsular bag. Proximal to the equatorial region are radial arms 115 and then a flexion zone 110 that attaches them to the optic ring. The haptics 100 are shaped set to be angled posteriorly, as much as at 45 degrees in resting position. In contrast to the haptic structure depicted in FIGS. 5A and 5B, this embodiment has fewer restraining tabs, thereby allowing room for wide paddle-like structures 280, attached to the radial arms 115 that overlay compression zones 285 in the optic 105 and can exert pressure on these thin zones of the optic vesicle to shift fluid during accommodation. The paddle-like structures 280 may be made from nitinol, preferably from the same sheet and same thickness as the remainder of the haptic system, and have dimensions of, e.g., 100×500 microns, to encompass as much of the optic flexion zone 110 as possible. If necessary, the paddle 280 can be stiffened by addition of additional material bonded to it, or by folding over some of the same material, and can be shape set to the curvature of the optic 105, to drive as much fluid as possible.


The anterior capsule 180 includes a central optical zone 165 and a thicker fusion zone 290 in the periphery, adapted to bond to the fusion zone of the posterior optic. The fusion zones have rounded edges to create channels or spaces 295 where excess bonding material can bead and collect rather than spread toward the optical surface. The central anterior capsule is made of shape memory silicone elastomer and may be as thin as 25-50 microns. The thickness of the optical zone may be uniform throughout or change gradually from the center to the periphery. The anterior capsule provides the accommodative component of the IOL.


The posterior capsule 185 is substantially thicker, to resist distortion during accommodation, and it also has a central optical zone 200 and a peripheral fusion zone 195. The fusion zone has similar rounded edges to allow excess bonding material to bead in circumferential spaces 295 and not spread toward the optical surface or haptic arms 115. The optical zone carries the patient's prescription power, the power needed to correct the patient's aphakic refractive error including possibly astigmatic error. The axis of the astigmatic correction is marked externally. The anterior equatorial zone of the posterior capsule has compressible 285 and non-compressible 300 zones. The compressible zones 285 are immediately below the paddle 280 elements of the haptics 100 and are very thin, so that they can be easily squeezed by the haptics 100. The non-compressible zones 300 are located under the restraining tabs of the haptic 100. Here, the equatorial zones of the anterior and posterior capsules are fused with pillars or ribs 305. This imparts structural rigidity to the posterior optical surface when pressure is applied by haptics 100 to the compressible zones 295.


In this embodiment, zonular axial pull causes flattening of the haptic structure and posterior axial shift. When the zonular tension abates, the haptics 100 flex posteriorly towards the visual axis and axially shift the optic anteriorly and also shape shift the optic geometry. The flexible optic of this embodiment is fluid filled and adapted to change to a more accommodated, convex configuration of the thin anterior optic capsule when the haptics 100 press on thin peripheral compression zones shifting fluid centrally and anteriorly. The surface area of the thin anterior optic capsule, the accommodating element, may be altered, or stretched during accommodation, when additional volume of fluid is shifted be the haptics 100 compression and the optical zone becomes more spherical. These changes maintain the proper volume/surface area ratio required by the geometry of the accommodated optic 105. The thickness of the compression zones may be as little as 25-50 microns, and the compression zone may be thinner and more stretchable than the anterior optical zone.


The internal cavity 205 is filled with fluid having a greater index of refraction than water, such as silicone oil for example, and preferably with the same index of refraction as the elastomer used for the anterior and posterior capsule elements. The cavity 205 is filled to its disaccommodated shape, where the optical zone is generally not stretched but the compression zones may or may not be stretched, depending on their thicknesses and desired balance of opposing forces. Biocompatible sutures or rings are used to suspend the haptics 100 to the restraining tabs, giving the haptics 100 a generally horizontal configuration, in the same plane with the optic ring and the closed capsular bag prior to implantation. The sutures or rings are amendable to being sectioned by an external, non-invasive laser, such as YAG or femtosecond. After several weeks post implantation, once the capsular bag has closed, fused and fibrosed, trapping the haptics within, the suture or ring is cut and radial cuts in the capsular bag may also be performed between haptics 100. This allows the haptic system to move in response to zonular tension. During accommodation, the zonular tension abates, the haptics 100 can move towards their resting state, vaulting posteriorly and compressing the compression zones in between. This compression shifts the internal fluid centrally and forward and bows the anterior optical surface to a more convex, accommodated configuration. When zonular tension resumes during disaccommodation, the haptics 100 are pulled apart and the stretch of the anterior optical zone pushes fluid down and out and fills the compression zones.


The two optical components are made of shape memory elastomer, such as silicone, and preferably of a different silicone family than the fluid filling the optic vesicle. They are molded separately and assembled together with the haptic ring and bonded. The fusion zones ensure both centration of the two optical components and also the trapping of the optic ring between the two optical components, which helps to stabilize the structure of the IOL.


The haptic system is made of nitinol, laser cut from a sheet that may be as thin as 0.0001″ or 0.0002″, shape set to its resting accommodated configuration and chemically surface treated to increase its biocompatibility and reduce laser induced irregularities. Once the three components are assembled and bonded, the cavity is filled with fluid, such as silicone oil, with a needle passing tangentially through a thicker area of the lens.


While several aspects of the present invention have been described and depicted herein, alternative aspects may be effected by those skilled in the art to accomplish the same objectives. Accordingly, it is intended that the appended claims cover all such alternative aspects as fall within the true spirit and scope of the invention.

Claims
  • 1. A dual mode accommodative-disaccommodative intraocular lens (dual mode AD-IOL) comprising: a haptic system comprising a plurality of closed-loop haptics having shape memory;a shape-shifting flexible optic comprising an anterior optic capsule and a posterior optic capsule, each of the two capsules comprising a fusion zone and the fusion zones of the two capsules being fused together, thereby defining therebetween an optic vesicle, the optic vesicle being filled with a fluid, wherein (i) the haptics are attached to the optic, allowing an action of the haptics to alter a shape of the optic, (ii) the shape-shifting flexible optic has a diameter of ≤8 mm and (iii) the dual mode AD-IOL, at rest, is in a fully accommodated configuration as a result of at least one of the shape memory of the haptic system and a shape-shifting capability of the flexible optic; anda restraining component sized and configured to immobilize the haptic in at least one of a flatter angle and a larger diameter in a disaccommodated configuration of the AD-IOL, when compared to the accommodated configuration.
  • 2. The dual-mode ID-IOL of claim 1, wherein the closed-loop haptics are at least one of trapezoidal and T-shaped.
  • 3. The dual-mode AD-IOL of claim 1, further comprising: an optic ring,wherein the optic ring connects the haptics to each other and to the optic.
  • 4. The dual-mode AD-IOL of claim 1, wherein the haptics are attached to the optic by a portion of each haptic being embedded in the optic at the fusion zone.
  • 5. The dual-mode AD-IOL of claim 1, wherein each closed-loop haptic is configured to adapted to transmit to the optic radial pull created by zonular tension during disaccommodation of the AD-IOL.
  • 6. The dual-mode AD-IOL of claim 1, wherein each closed-loop haptic is configured to adapted to return to a set shape during accommodation of the AD-IOL.
  • 7. The dual-mode AD-IOL of claim 1, wherein the restraining component is selected from the group consisting of a restraining tab disposed on a haptic or an optic ring, a restraining hole defined by a haptic portion, a restraining hole defined by an optic in a fusion zone thereof, a cross bar on a haptic arm, a restraining ring, and a suture.
  • 8. The dual-mode AD-IOL of claim 1, further comprising a ring-shaped plate embedded between an anterior optic capsule and a posterior optic capsule of the optic.
  • 9. The dual-mode AD-IOL of claim 1, wherein each of the closed-loop haptics comprises a first connecting feature and the optic comprises a second connecting feature adapted to engage with the first connecting feature.
  • 10. The dual-mode AD-IOL of claim 1, wherein each of the closed-loop haptics is shape set to contribute to axial shift and shape shift of the optic.
  • 11. The dual-mode AD-IOL of claim 1, wherein the haptic system comprises at least two optic rings, each optic ring comprising two closed-loop haptics, the optic rings being disposed over the optic and configured to rotate to overlay the haptics of a first optic ring over the haptics of a proximate optic ring, to reduce a profile thereof to facilitate loading of the dual-mode AD-IOL in an injector.
  • 12. The dual-mode AD-IOL of claim 1, wherein at least one closed-loop haptic comprises a radial segment and a paddle being disposed on the radial segment configured to compress a portion of the optic.
  • 13. The dual-mode AD-IOL of claim 1, wherein a sum of at least an accommodative memory or a disaccommodative memory of the optic and the haptic system is less than 1 gram force.
  • 14. The dual-mode AD-IOL of claim 1, wherein the anterior and posterior optic capsules are fused with a bonding material and the fusion zone defines a channel configured to receive excess bonding material.
  • 15. The dual-mode AD-IOL of claim 1, wherein a change in a shape of the flexible optic changes a ratio of a surface area of the optic vesicle to a volume of the optic vesicle and the haptic system changes size and shape to accommodate the change in the ratio.
  • 16. The dual-mode AD-IOL of claim 1, wherein one of the optic capsules comprises a thick, rigid optical zone carrying a fixed refractive power including astigmatic correction, a thickness of the thick rigid optical zone being selected from a range of 200 to 500 microns with the thickness being greater than a thickness of a flexion zone disposed proximate the thick, rigid optical zone.
  • 17. The dual-mode AD-IOL of claim 1, wherein one of the optic capsules comprises a thinner, more easily distorted flexion zone disposed proximate a central optical zone.
  • 18. The dual-mode AD-IOL of claim 1, wherein the optic vesicle has shape memory.
  • 19. The dual-mode AD-IOL of claim 1, wherein the haptic system is adapted to fit within an IOL injection system.
  • 20. A method for implanting a dual-mode accommodative-disaccommodative intraocular lens (AD-IOL), comprising the steps of: providing an AD-IOL comprising: a haptic system comprising a plurality of closed-loop haptics having shape memory;a shape-shifting flexible optic comprising an anterior optic capsule and a posterior optic capsule, each of the two capsules comprising a fusion zone and the fusion zones of the two capsules being fused together, thereby defining therebetween an optic vesicle, the optic vesicle being filled with a fluid, wherein (i) the haptics are attached to the optic, allowing an action of the haptics to alter a shape of the optic, (ii) the shape-shifting flexible optic has a diameter of ≤8 mm and (iii) the dual mode AD-IOL, at rest, is in a fully accommodated configuration as a result of at least one of the shape memory of the haptic system and a shape-shifting capability of the flexible optic; anda restraining component sized and configured to immobilize the haptic in at least one of a flatter angle and a larger diameter in a disaccommodated configuration of the AD-IOL, when compared to the accommodated configuration;implanting the AD-IOL into an eye of a patient;allowing a capsular bag of the eye to fuse through the haptics; andreleasing the haptics by making radial cuts therebetween, the radial cuts extending from edges of the eye's anterior capsule towards an equator of the eye's capsular bag for a distance defined to produce a desired amount of release in stiffness of the eye's fibrosed capsular bag.
RELATED APPLICATION

This application claims priority to and the benefit of U.S. Provisional Patent Application Ser. No. 62/378,737 filed on Aug. 24, 2016, the disclosure of which is hereby incorporated by reference in its entirety.

US Referenced Citations (822)
Number Name Date Kind
3975779 Richards et al. Aug 1976 A
3979780 Boniuk Sep 1976 A
3991426 Flom et al. Nov 1976 A
4053953 Flom et al. Oct 1977 A
4056855 Kelman Nov 1977 A
4124905 Clark Nov 1978 A
4149279 Poler Apr 1979 A
4262370 Hartstein Apr 1981 A
4373218 Schachar Feb 1983 A
4463457 Kelman Aug 1984 A
4527294 Heslin Jul 1985 A
4534069 Kelman Aug 1985 A
4575373 Johnson Mar 1986 A
4581032 Grandon Apr 1986 A
4581033 Callahan Apr 1986 A
4588406 Fedorov et al. May 1986 A
4666446 Koziol et al. May 1987 A
4685922 Peyman Aug 1987 A
4693717 Michelson Sep 1987 A
4718904 Thornton Jan 1988 A
4738680 Herman Apr 1988 A
4781719 Kelman Nov 1988 A
4787903 Grendahl Nov 1988 A
4790847 Woods Dec 1988 A
4842601 Smith Jun 1989 A
4871363 Kelman Oct 1989 A
4878910 Koziol et al. Nov 1989 A
4888012 Horn et al. Dec 1989 A
4888015 Domino Dec 1989 A
4892543 Turley Jan 1990 A
4932966 Christie et al. Jun 1990 A
4932968 Caldwell et al. Jun 1990 A
4936850 Barrett Jun 1990 A
4944082 Jones et al. Jul 1990 A
4950288 Kelman Aug 1990 A
4955894 Herman Sep 1990 A
4963148 Sulc et al. Oct 1990 A
4995879 Dougherty Feb 1991 A
5104590 Blake Apr 1992 A
5108429 Wiley Apr 1992 A
5185107 Blake Feb 1993 A
5192319 Worst Mar 1993 A
RE34424 Walman Oct 1993 E
5282851 Jacob-LaBarre Feb 1994 A
5288293 O'Donnell, Jr. Feb 1994 A
5306297 Rheinish et al. Apr 1994 A
5326347 Cumming Jul 1994 A
5366500 Schneider et al. Nov 1994 A
5423929 Doyle et al. Jun 1995 A
5476514 Cumming Dec 1995 A
5489302 Skottun Feb 1996 A
5496366 Cumming Mar 1996 A
5507806 Blake Apr 1996 A
5527415 Doyle et al. Jun 1996 A
5549668 O'Donnell, Jr. Aug 1996 A
5562731 Cumming Oct 1996 A
5571177 Deacon et al. Nov 1996 A
5578081 McDonald Nov 1996 A
5593436 Langerman Jan 1997 A
5607472 Thompson Mar 1997 A
5674282 Cumming Oct 1997 A
5683456 Blake Nov 1997 A
5702441 Zhou Dec 1997 A
5728155 Anello et al. Mar 1998 A
5728156 Gupta et al. Mar 1998 A
5769889 Kelman Jun 1998 A
5782911 Herrick Jul 1998 A
5800532 Lieberman Sep 1998 A
5803925 Yang et al. Sep 1998 A
5843187 Bayers Dec 1998 A
5855605 Herrick Jan 1999 A
5964802 Anello et al. Oct 1999 A
5984962 Anello et al. Nov 1999 A
6013101 Israel Jan 2000 A
6015435 Valunin et al. Jan 2000 A
6027531 Tassignon Feb 2000 A
6048364 Skottun Apr 2000 A
6051024 Cumming Apr 2000 A
6053944 Tran et al. Apr 2000 A
6083261 Callahan et al. Jul 2000 A
6096077 Callahan et al. Aug 2000 A
6096078 McDonald Aug 2000 A
6110202 Barraquer et al. Aug 2000 A
6139576 Doyle et al. Oct 2000 A
6143027 Ratner et al. Nov 2000 A
6152959 Portney Nov 2000 A
6171337 Galin Jan 2001 B1
6176878 Gwon et al. Jan 2001 B1
6179843 Weiler Jan 2001 B1
6190410 Lamielle et al. Feb 2001 B1
6197058 Portney Mar 2001 B1
6197059 Cumming Mar 2001 B1
6200342 Tassignon Mar 2001 B1
6200344 Lamielle et al. Mar 2001 B1
6217612 Woods Apr 2001 B1
6224628 Callahan et al. May 2001 B1
6228115 Hoffmann et al. May 2001 B1
6241777 Kellan Jun 2001 B1
6251312 Phan et al. Jun 2001 B1
6261321 Kellan Jul 2001 B1
6280449 Blake Aug 2001 B1
6299641 Woods Oct 2001 B1
6302912 Bernau Oct 2001 B1
6306167 Bernau et al. Oct 2001 B1
6358280 Herrick Mar 2002 B1
6387126 Cumming May 2002 B1
6398809 Hoffmann et al. Jun 2002 B1
6406494 Laguette et al. Jun 2002 B1
6413262 Saishin et al. Jul 2002 B2
6413277 Neuhann Jul 2002 B1
6423094 Sarfarazi Jul 2002 B1
6425917 Blake Jul 2002 B1
6428574 Valunin et al. Aug 2002 B1
6432246 Blake Aug 2002 B1
6443984 Jahn et al. Sep 2002 B1
6443985 Woods Sep 2002 B1
6451056 Cumming Sep 2002 B1
6461384 Hoffmann et al. Oct 2002 B1
6464725 Skotton Oct 2002 B2
6475240 Paul Nov 2002 B1
6482229 Gwon et al. Nov 2002 B1
6488707 Callahan et al. Dec 2002 B1
6488708 Sarfarazi Dec 2002 B2
6488709 Barrett Dec 2002 B1
6494911 Cumming Dec 2002 B2
6503276 Lang et al. Jan 2003 B2
6517577 Callahan et al. Feb 2003 B1
6524340 Israel Feb 2003 B2
6537317 Steinert et al. Mar 2003 B1
6543453 Klima et al. Apr 2003 B1
6547822 Lang Apr 2003 B1
6554859 Lang et al. Apr 2003 B1
6558395 Hjertman et al. May 2003 B2
6558420 Green May 2003 B2
6576012 Lang Jun 2003 B2
6592621 Domino Jul 2003 B1
6596025 Portney Jul 2003 B2
6605093 Blake Aug 2003 B1
6616692 Glick et al. Sep 2003 B1
6638306 Cumming Oct 2003 B2
6660035 Lang et al. Dec 2003 B1
6666887 Callahan et al. Dec 2003 B1
6695881 Peng et al. Feb 2004 B2
6730123 Klopotek May 2004 B1
6749634 Hanna Jun 2004 B2
6755859 Hoffmann et al. Jun 2004 B2
6761737 Zadno-Azizi et al. Jul 2004 B2
6764511 Zadno-Azizi et al. Jul 2004 B2
6767363 Bandhauer et al. Jul 2004 B1
6786928 Callahan et al. Sep 2004 B2
6786934 Zadno-Azizi et al. Sep 2004 B2
6790232 Lang Sep 2004 B1
6797003 Blake et al. Sep 2004 B1
6800091 Callahan et al. Oct 2004 B2
6824563 Lang Nov 2004 B2
6836374 Esch et al. Dec 2004 B2
6846326 Zadno-Azizi et al. Jan 2005 B2
6849091 Cumming Feb 2005 B1
6855164 Glazier Feb 2005 B2
6858040 Nguyen et al. Feb 2005 B2
6860601 Shadduck Mar 2005 B2
6884261 Zadno-Azizi et al. Apr 2005 B2
6899732 Zadno-Azizi et al. May 2005 B2
6918930 Portney Jul 2005 B2
6921415 Callahan et al. Jul 2005 B2
6921416 Khoury Jul 2005 B2
6926736 Peng et al. Aug 2005 B2
6926744 Bos et al. Aug 2005 B1
6932839 Kamerling et al. Aug 2005 B1
6935743 Shadduck Aug 2005 B2
6966649 Shadduck Nov 2005 B2
6969403 Peng et al. Nov 2005 B2
6986763 Holmen Jan 2006 B2
6986787 Baker, Jr. Jan 2006 B1
6991651 Portney Jan 2006 B2
7025783 Brady et al. Apr 2006 B2
7036931 Lindacher et al. May 2006 B2
7037338 Nagamoto May 2006 B2
7041134 Nguyen et al. May 2006 B2
7048759 Bogaert et al. May 2006 B2
7048760 Cumming May 2006 B2
7060094 Shahinpoor et al. Jun 2006 B2
7063723 Ran Jun 2006 B2
7068439 Esch et al. Jun 2006 B2
7087080 Zadno-Azizi et al. Aug 2006 B2
7097660 Portney Aug 2006 B2
7118596 Zadno-Azizi et al. Oct 2006 B2
7118597 Miller et al. Oct 2006 B2
7122053 Esch Oct 2006 B2
7125422 Woods et al. Oct 2006 B2
7137702 Piers et al. Nov 2006 B2
7150759 Paul et al. Dec 2006 B2
7150760 Zhang Dec 2006 B2
7192444 Blake et al. Mar 2007 B2
7198640 Nguyen Apr 2007 B2
7204849 Portney Apr 2007 B2
7217288 Esch et al. May 2007 B2
7220279 Nun May 2007 B2
7226478 Ting et al. Jun 2007 B2
7229475 Glazier Jun 2007 B2
7238201 Portney et al. Jul 2007 B2
7247168 Esch et al. Jul 2007 B2
7261737 Esch et al. Aug 2007 B2
7264351 Shadduck Sep 2007 B2
7278739 Shadduck Oct 2007 B2
7354451 Koch Apr 2008 B2
7377640 Piers et al. May 2008 B2
7381221 Lang et al. Jun 2008 B2
7384429 Hanna Jun 2008 B2
7404637 Miller et al. Jul 2008 B2
7404638 Miller et al. Jul 2008 B2
7435259 Cumming Oct 2008 B2
7438723 Esch Oct 2008 B2
7452362 Zadno-Azizi et al. Nov 2008 B2
7452378 Zadno-Azizi et al. Nov 2008 B2
7455691 Feingold et al. Nov 2008 B2
7462193 Nagamoto Dec 2008 B2
7485144 Esch Feb 2009 B2
7494505 Kappelhof et al. Feb 2009 B2
7503938 Phillips Mar 2009 B2
7553327 Cumming Jun 2009 B2
7569073 Vaudant et al. Aug 2009 B2
7591849 Richardson Sep 2009 B2
7601169 Phillips Oct 2009 B2
7615056 Ayton et al. Nov 2009 B2
7615073 Deacon et al. Nov 2009 B2
7621949 Deacon et al. Nov 2009 B2
7637947 Smith et al. Dec 2009 B2
7662179 Sarfarazi Feb 2010 B2
7670371 Piers et al. Mar 2010 B2
7674288 Nagamoto Mar 2010 B2
7713299 Brady et al. May 2010 B2
7722670 Elahi et al. May 2010 B2
7744646 Zadno-Azizi et al. Jun 2010 B2
7744647 Barrett Jun 2010 B2
7763069 Brady et al. Jul 2010 B2
7763070 Cumming Jul 2010 B2
7771471 Dell Aug 2010 B2
7776088 Shadduck Aug 2010 B2
7780729 Nguyen et al. Aug 2010 B2
7790824 Freeman Sep 2010 B2
7790825 Lehman et al. Sep 2010 B2
7794497 Brady et al. Sep 2010 B2
7794498 Pinchuk Sep 2010 B2
7806930 Brown Oct 2010 B2
7811320 Werblin Oct 2010 B2
7815678 Ben Nun Oct 2010 B2
7837730 Cumming et al. Nov 2010 B2
7842087 Ben Nun Nov 2010 B2
7854764 Ben Nun Dec 2010 B2
7857850 Mentak et al. Dec 2010 B2
7871437 Hermans et al. Jan 2011 B2
7878655 Salvati et al. Feb 2011 B2
7883540 Niwa et al. Feb 2011 B2
7905917 Altmann Mar 2011 B2
7931686 Vaudant et al. Apr 2011 B2
7942889 Assia May 2011 B2
7981155 Cumming Jul 2011 B2
7985253 Cumming Jul 2011 B2
7998198 Angelopoulos et al. Aug 2011 B2
7998199 Ben Nun Aug 2011 B2
8012204 Weinschenk, III et al. Sep 2011 B2
8034106 Mentak et al. Oct 2011 B2
8034107 Stenger Oct 2011 B2
8034108 Bumbalough Oct 2011 B2
8038711 Clarke Oct 2011 B2
8043370 Bretthauer et al. Oct 2011 B2
8043372 Bumbalough Oct 2011 B2
8048155 Shadduck Nov 2011 B2
8048156 Geraghty et al. Nov 2011 B2
8052752 Woods et al. Nov 2011 B2
8062361 Nguyen et al. Nov 2011 B2
8062362 Brady et al. Nov 2011 B2
8066768 Werblin Nov 2011 B2
8066769 Werblin Nov 2011 B2
8070806 Khoury Dec 2011 B2
8080017 Tanaka Dec 2011 B2
8100965 Cumming et al. Jan 2012 B2
8109998 Cumming Feb 2012 B2
8123729 Yamamoto et al. Feb 2012 B2
8133273 Aharoni et al. Mar 2012 B2
8158712 Your Apr 2012 B2
8163015 Cumming Apr 2012 B2
8167941 Boyd et al. May 2012 B2
8182531 Hermans et al. May 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8206442 Sel et al. Jun 2012 B2
8215770 Blum et al. Jul 2012 B2
8216305 Salvati et al. Jul 2012 B2
8216306 Coroneo Jul 2012 B2
8216308 Blake et al. Jul 2012 B2
8231672 Deacon et al. Jul 2012 B2
8235525 Lesage et al. Aug 2012 B2
8241353 Deacon et al. Aug 2012 B2
8241355 Brady et al. Aug 2012 B2
8246679 Nguyen et al. Aug 2012 B2
8267996 Niwa et al. Sep 2012 B2
8273123 Ben Nun Sep 2012 B2
8303656 Shadduck Nov 2012 B2
8314927 Choi et al. Nov 2012 B2
8328869 Smiley et al. Dec 2012 B2
8343216 Brady et al. Jan 2013 B2
8343217 Bumbalough Jan 2013 B2
8349006 Zhao et al. Jan 2013 B2
8357196 Jain et al. Jan 2013 B2
8361145 Scholl et al. Jan 2013 B2
8366653 Shareef et al. Feb 2013 B2
8377123 Evans et al. Feb 2013 B2
8377125 Kellan Feb 2013 B2
8382831 Ben Nun Feb 2013 B2
8382832 Deacon et al. Feb 2013 B2
8398709 Ben Nun Mar 2013 B2
8403984 Tsai et al. Mar 2013 B2
8414646 De Juan, Jr. et al. Apr 2013 B2
8425595 Tsai et al. Apr 2013 B2
8425597 Glick et al. Apr 2013 B2
8425598 Klink et al. Apr 2013 B2
8425599 Shadduck Apr 2013 B2
8430928 Liao Apr 2013 B2
8435289 Cole et al. May 2013 B2
8447086 Hildebrand et al. May 2013 B2
8449611 Richardson May 2013 B2
8454688 Esch et al. Jun 2013 B2
8465544 Brady et al. Jun 2013 B2
8475527 Peterson et al. Jul 2013 B2
8475529 Clarke Jul 2013 B2
8480734 Kellan et al. Jul 2013 B2
8486140 Willis et al. Jul 2013 B2
8486141 Lang et al. Jul 2013 B2
8486142 Bumbalough et al. Jul 2013 B2
8496701 Hermans et al. Jul 2013 B2
8500804 Brady et al. Aug 2013 B2
8500806 Phillips Aug 2013 B1
8523942 Cumming Sep 2013 B2
8529623 Piers et al. Sep 2013 B2
8535376 Altmann Sep 2013 B2
8545556 Woods et al. Oct 2013 B2
8551164 Willis et al. Oct 2013 B2
8551167 Cuevas Oct 2013 B2
8556967 Sarfarazi Oct 2013 B2
8562674 Cole et al. Oct 2013 B2
8568478 Zickler et al. Oct 2013 B2
8574293 Kappelhof et al. Nov 2013 B2
8579971 Webb Nov 2013 B2
8579972 Rombach Nov 2013 B2
8585758 Woods Nov 2013 B2
8585759 Bumbalough Nov 2013 B2
8608799 Blake Dec 2013 B2
8608800 Portney Dec 2013 B2
8613766 Richardson et al. Dec 2013 B2
8623082 Kappelhof et al. Jan 2014 B2
8647384 Lu Feb 2014 B2
8652206 Masket Feb 2014 B2
8657877 Glazier Feb 2014 B2
8657878 Mentak et al. Feb 2014 B2
8668734 Hildebrand et al. Mar 2014 B2
8900298 Anvar et al. Dec 2014 B2
8956408 Smiley et al. Feb 2015 B2
8968396 Matthews et al. Mar 2015 B2
8992609 Shadduck Mar 2015 B2
9044317 Hildebrand et al. Jun 2015 B2
9072600 Tran Jul 2015 B2
9186244 Silvestrini et al. Nov 2015 B2
9220590 Beer Dec 2015 B2
9277987 Smiley et al. Mar 2016 B2
9364318 Beer Jun 2016 B2
9456895 Shadduck Oct 2016 B2
9610155 Matthews Apr 2017 B2
9693858 Hildebrand et al. Jul 2017 B2
9795473 Smiley et al. Oct 2017 B2
9855137 Smiley et al. Jan 2018 B2
9855139 Matthews et al. Jan 2018 B2
9872762 Scholl et al. Jan 2018 B2
9872763 Smiley et al. Jan 2018 B2
10004596 Brady et al. Jun 2018 B2
10045844 Smiley et al. Aug 2018 B2
10111745 Silvestrini et al. Oct 2018 B2
10159564 Brady et al. Dec 2018 B2
10195020 Matthews Feb 2019 B2
20010001836 Cumming May 2001 A1
20010012964 Lang et al. Aug 2001 A1
20010016771 Cumming Aug 2001 A1
20010044657 Kellan Nov 2001 A1
20010051826 Bogaert et al. Dec 2001 A1
20020002404 Sarfarazi Jan 2002 A1
20020013622 Hennig Jan 2002 A1
20020016630 Lang Feb 2002 A1
20020045937 Sarfarazi Apr 2002 A1
20020051063 Hwang May 2002 A1
20020072673 Yamamoto et al. Jun 2002 A1
20020072795 Green Jun 2002 A1
20020101564 Herrick Aug 2002 A1
20020103535 Portney Aug 2002 A1
20020107568 Zadno-Azizi et al. Aug 2002 A1
20020111678 Zadno-Azizi et al. Aug 2002 A1
20020116057 Ting et al. Aug 2002 A1
20020116058 Zadno-Azizi et al. Aug 2002 A1
20020116059 Zadno-Azizi et al. Aug 2002 A1
20020116060 Nguyen et al. Aug 2002 A1
20020116061 Zadno-Azizi et al. Aug 2002 A1
20020116062 Portney Aug 2002 A1
20020133228 Sarver Sep 2002 A1
20020138140 Hanna Sep 2002 A1
20020138141 Zadno-Azizi et al. Sep 2002 A1
20020143395 Skottun Oct 2002 A1
20020161435 Portney Oct 2002 A1
20020173847 Pham et al. Nov 2002 A1
20020177896 Israel Nov 2002 A1
20020183843 Blake et al. Dec 2002 A1
20020193876 Lang et al. Dec 2002 A1
20020193877 Hoffmann et al. Dec 2002 A1
20030018386 Laguette et al. Jan 2003 A1
20030033011 Singer et al. Feb 2003 A1
20030033013 Callahan et al. Feb 2003 A1
20030060878 Shadduck Mar 2003 A1
20030065387 Callahan et al. Apr 2003 A1
20030074060 Zadno-Azizi et al. Apr 2003 A1
20030074061 Pham et al. Apr 2003 A1
20030078655 Callahan et al. Apr 2003 A1
20030078656 Nguyen Apr 2003 A1
20030078657 Zadno-Azizi et al. Apr 2003 A1
20030078658 Zadno-Azizi Apr 2003 A1
20030083744 Khoury May 2003 A1
20030093149 Glazier May 2003 A1
20030105522 Glazier Jun 2003 A1
20030109926 Portney Jun 2003 A1
20030114927 Nagamoto Jun 2003 A1
20030130732 Sarfarazi Jul 2003 A1
20030135271 Bandhauer Jul 2003 A1
20030135273 Callahan et al. Jul 2003 A1
20030147046 Shadduck Aug 2003 A1
20030149480 Shadduck Aug 2003 A1
20030171808 Phillips Sep 2003 A1
20030171809 Phillips Sep 2003 A1
20030181977 Brady Sep 2003 A1
20030187504 Weinschenk et al. Oct 2003 A1
20030199976 Portney Oct 2003 A1
20030204254 Peng et al. Oct 2003 A1
20030204255 Peng et al. Oct 2003 A1
20030204256 Peng et al. Oct 2003 A1
20040015236 Sarfarazi et al. Jan 2004 A1
20040034417 Heyman Feb 2004 A1
20040064182 Kelman Apr 2004 A1
20040073304 Weinschenk, III et al. Apr 2004 A1
20040082993 Woods Apr 2004 A1
20040082994 Woods et al. Apr 2004 A1
20040082995 Woods Apr 2004 A1
20040100704 Shadduck May 2004 A1
20040106992 Lang et al. Jun 2004 A1
20040106993 Portney Jun 2004 A1
20040111152 Kelman Jun 2004 A1
20040111153 Woods et al. Jun 2004 A1
20040117013 Schachar Jun 2004 A1
20040158322 Shen Aug 2004 A1
20040162612 Portney et al. Aug 2004 A1
20040169816 Esch Sep 2004 A1
20040169932 Esch et al. Sep 2004 A1
20040181279 Nun Sep 2004 A1
20040184158 Shadduck Sep 2004 A1
20040190153 Esch Sep 2004 A1
20040215340 Messner et al. Oct 2004 A1
20040230300 Bandhauer et al. Nov 2004 A1
20040236422 Zhang et al. Nov 2004 A1
20040236423 Zhang et al. Nov 2004 A1
20040243233 Phillips Dec 2004 A1
20040249455 Tran Dec 2004 A1
20050021137 Blake et al. Jan 2005 A1
20050021138 Woods Jan 2005 A1
20050021139 Shadduck Jan 2005 A1
20050049700 Zadno-Azizi et al. Mar 2005 A1
20050055092 Nguyen et al. Mar 2005 A1
20050060032 Magnante et al. Mar 2005 A1
20050071002 Glazier Mar 2005 A1
20050075732 Israel Apr 2005 A1
20050085907 Hanna Apr 2005 A1
20050090896 Ben Nun Apr 2005 A1
20050096741 Cumming May 2005 A1
20050107873 Zhou May 2005 A1
20050107875 Cumming May 2005 A1
20050113914 Miller et al. May 2005 A1
20050119739 Glazier Jun 2005 A1
20050119740 Esch et al. Jun 2005 A1
20050125055 Deacon et al. Jun 2005 A1
20050125057 Cumming Jun 2005 A1
20050125059 Pinchuk et al. Jun 2005 A1
20050131535 Woods Jun 2005 A1
20050137703 Chen Jun 2005 A1
20050143814 Esch et al. Jun 2005 A1
20050149183 Shadduck Jul 2005 A1
20050149184 Bogaert Jul 2005 A1
20050209692 Zhang Sep 2005 A1
20050234547 Nguyen et al. Oct 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen et al. Dec 2005 A1
20060020339 Ran Jan 2006 A1
20060030938 Altmann Feb 2006 A1
20060041307 Esch et al. Feb 2006 A1
20060047339 Brown Mar 2006 A1
20060047340 Brown Mar 2006 A1
20060061729 Shadduck Mar 2006 A1
20060064162 Klima Mar 2006 A1
20060069433 Nun Mar 2006 A1
20060087614 Shadduck Apr 2006 A1
20060089712 Malecaze Apr 2006 A1
20060092340 Blum et al. May 2006 A1
20060100701 Esch et al. May 2006 A1
20060100703 Evans et al. May 2006 A1
20060100704 Blake et al. May 2006 A1
20060116765 Blake et al. Jun 2006 A1
20060142855 Vaudant et al. Jun 2006 A1
20060149369 Cumming et al. Jul 2006 A1
20060178741 Zadno-Azizi et al. Aug 2006 A1
20060178742 Nagamoto Aug 2006 A1
20060184244 Nguyen et al. Aug 2006 A1
20060212116 Woods Sep 2006 A1
20060212117 Lang et al. Sep 2006 A1
20060247766 Marin Nov 2006 A1
20060247767 Koch Nov 2006 A1
20060253196 Woods Nov 2006 A1
20060259139 Zadno-Azizi et al. Nov 2006 A1
20060259140 Dell Nov 2006 A1
20060271186 Nishi et al. Nov 2006 A1
20060271187 Zadno-Azizi et al. Nov 2006 A1
20070005135 Makker et al. Jan 2007 A1
20070005136 Richardson Jan 2007 A1
20070010880 Esch Jan 2007 A1
20070010882 Barrett Jan 2007 A1
20070016293 Tran Jan 2007 A1
20070021831 Clarke Jan 2007 A1
20070021832 Nordan Jan 2007 A1
20070027540 Zadno-Azizi et al. Feb 2007 A1
20070032866 Portney Feb 2007 A1
20070050024 Zhang Mar 2007 A1
20070050025 Nguyen et al. Mar 2007 A1
20070067030 Glazier et al. Mar 2007 A1
20070078515 Brady Apr 2007 A1
20070083260 Colvard Apr 2007 A1
20070083261 Colvard Apr 2007 A1
20070088433 Esch et al. Apr 2007 A1
20070100444 Brady et al. May 2007 A1
20070100445 Shadduck May 2007 A1
20070106377 Smith et al. May 2007 A1
20070106380 Terwee et al. May 2007 A1
20070106381 Blake May 2007 A1
20070108643 Zadno-Azizi et al. May 2007 A1
20070118216 Pynson May 2007 A1
20070123981 Tassignon May 2007 A1
20070129798 Chawdhary Jun 2007 A1
20070129803 Cumming et al. Jun 2007 A1
20070135915 Klima Jun 2007 A1
20070142913 Phillips Jun 2007 A1
20070156236 Stenger Jul 2007 A1
20070171366 Su et al. Jul 2007 A1
20070185574 Ben Nun Aug 2007 A1
20070203578 Scholl et al. Aug 2007 A1
20070213817 Esch et al. Sep 2007 A1
20070239274 Kellan Oct 2007 A1
20070244560 Ossipov et al. Oct 2007 A1
20070244561 Ben Nun Oct 2007 A1
20070260308 Tran Nov 2007 A1
20070260309 Richardson Nov 2007 A1
20070260310 Richardson Nov 2007 A1
20070270946 Poley Nov 2007 A1
20070299487 Shadduck Dec 2007 A1
20080004699 Ben Nun Jan 2008 A1
20080015689 Esch et al. Jan 2008 A1
20080021549 Eagan et al. Jan 2008 A1
20080021550 Richardson Jan 2008 A1
20080033449 Cole et al. Feb 2008 A1
20080046074 Smith et al. Feb 2008 A1
20080046075 Esch et al. Feb 2008 A1
20080046076 Rombach Feb 2008 A1
20080051801 Hovey et al. Feb 2008 A1
20080077238 Deacon et al. Mar 2008 A1
20080077239 Zickler et al. Mar 2008 A1
20080086206 Nasiatka et al. Apr 2008 A1
20080086208 Nordan Apr 2008 A1
20080109077 Bos May 2008 A1
20080109078 Rozakis et al. May 2008 A1
20080154364 Richardson et al. Jun 2008 A1
20080161913 Brady et al. Jul 2008 A1
20080161914 Brady et al. Jul 2008 A1
20080183289 Werblin Jul 2008 A1
20080188930 Mentak et al. Aug 2008 A1
20080200982 Your Aug 2008 A1
20080208335 Blum et al. Aug 2008 A1
20080215147 Werblin Sep 2008 A1
20080243247 Poley et al. Oct 2008 A1
20080269642 Deacon et al. Oct 2008 A1
20080269882 Simpson et al. Oct 2008 A1
20080269885 Simpson et al. Oct 2008 A1
20080269886 Simpson et al. Oct 2008 A1
20080281417 Nagamoto Nov 2008 A1
20080300680 Joshua Dec 2008 A1
20080306587 Your Dec 2008 A1
20080306588 Smiley et al. Dec 2008 A1
20090005865 Smiley et al. Jan 2009 A1
20090005866 Cumming Jan 2009 A1
20090012609 Geraghty et al. Jan 2009 A1
20090018652 Hermans et al. Jan 2009 A1
20090027661 Choi et al. Jan 2009 A1
20090030425 Smiley et al. Jan 2009 A1
20090033863 Blum et al. Feb 2009 A1
20090036982 Aharoni et al. Feb 2009 A1
20090062912 Rombach Mar 2009 A1
20090124773 Zhou et al. May 2009 A1
20090125105 Lesage et al. May 2009 A1
20090125106 Weinschenk, III et al. May 2009 A1
20090149952 Shadduck Jun 2009 A1
20090171458 Kellan et al. Jul 2009 A1
20090187242 Weeber et al. Jul 2009 A1
20090198326 Zhou et al. Aug 2009 A1
20090204209 Tran Aug 2009 A1
20090204210 Pynson Aug 2009 A1
20090204211 Angelopoulos et al. Aug 2009 A1
20090210054 Weeber et al. Aug 2009 A1
20090228101 Zadno-Azizi Sep 2009 A1
20090234448 Weeber et al. Sep 2009 A1
20090234449 De Juan, Jr. et al. Sep 2009 A1
20090248152 Bumbalough Oct 2009 A1
20090248154 Dell Oct 2009 A1
20090264998 Mentak et al. Oct 2009 A1
20090264999 Cumming Oct 2009 A1
20090265000 Vaudant et al. Oct 2009 A1
20090292354 Gontijo et al. Nov 2009 A1
20090292355 Boyd et al. Nov 2009 A1
20090312836 Pinchuk et al. Dec 2009 A1
20090319040 Khoury Dec 2009 A1
20100016964 Werblin Jan 2010 A1
20100036490 Deacon et al. Feb 2010 A1
20100094412 Wensrich Apr 2010 A1
20100094415 Bumbalough Apr 2010 A1
20100121443 Michel et al. May 2010 A1
20100121444 Ben Nun May 2010 A1
20100131058 Shadduck May 2010 A1
20100131059 Callahan et al. May 2010 A1
20100131061 Callahan et al. May 2010 A1
20100134754 Hong et al. Jun 2010 A1
20100137983 Culbertson et al. Jun 2010 A1
20100152848 Williamson et al. Jun 2010 A1
20100179652 Yamamoto et al. Jul 2010 A1
20100179653 Argento et al. Jul 2010 A1
20100198349 Brady et al. Aug 2010 A1
20100204788 Van Noy Aug 2010 A1
20100211167 Glazier Aug 2010 A1
20100211170 Liao Aug 2010 A1
20100211171 Sarfarazi Aug 2010 A1
20100228260 Callahan et al. Sep 2010 A1
20100228344 Shadduck Sep 2010 A1
20100228346 Esch Sep 2010 A1
20100292789 Willis et al. Nov 2010 A1
20100318186 Bumbalough et al. Dec 2010 A1
20100324671 Shadduck Dec 2010 A1
20100324672 Esch et al. Dec 2010 A1
20100324673 Nguyen et al. Dec 2010 A1
20110029074 Reisin et al. Feb 2011 A1
20110035001 Woods Feb 2011 A1
20110035002 Nun Feb 2011 A1
20110040376 Christie et al. Feb 2011 A1
20110040378 Werblin Feb 2011 A1
20110040379 Bumbalough Feb 2011 A1
20110052020 Hildebrand et al. Mar 2011 A1
20110054600 Bumbalough Mar 2011 A1
20110054601 Kadziauskas et al. Mar 2011 A1
20110071628 Gross et al. Mar 2011 A1
20110082544 Ben Nun Apr 2011 A1
20110093067 Michalek et al. Apr 2011 A1
20110098810 Altmann Apr 2011 A1
20110098812 Ben Nun Apr 2011 A1
20110112635 Ben Nun May 2011 A1
20110112636 Ben Nun May 2011 A1
20110112638 Hermans et al. May 2011 A1
20110118836 Jain et al. May 2011 A1
20110153014 Zhang et al. Jun 2011 A1
20110153015 Simonov et al. Jun 2011 A1
20110160852 Mentak et al. Jun 2011 A1
20110184514 Angelopoulos et al. Jul 2011 A1
20110191086 Callahan et al. Aug 2011 A1
20110208301 Anvar et al. Aug 2011 A1
20110224788 Webb Sep 2011 A1
20110238174 Hong et al. Sep 2011 A1
20110245920 Richardson Oct 2011 A1
20110251686 Masket Oct 2011 A1
20110257742 Bumbalough et al. Oct 2011 A1
20110270389 Glazer et al. Nov 2011 A1
20110282441 Zadno-Azizi Nov 2011 A1
20110282442 Scholl et al. Nov 2011 A1
20110282443 Smiley et al. Nov 2011 A1
20110288638 Smiley et al. Nov 2011 A1
20110295368 Betser Dec 2011 A1
20110304058 Pendse Dec 2011 A1
20110307058 Beer Dec 2011 A1
20110313522 Hayes Dec 2011 A1
20110313523 Hayes Dec 2011 A1
20120010704 Bumbalough Jan 2012 A1
20120016473 Brady et al. Jan 2012 A1
20120022547 Hildebrand et al. Jan 2012 A1
20120029632 Ben Nun Feb 2012 A1
20120035724 Clarke Feb 2012 A1
20120046743 Pinchuk Feb 2012 A1
20120046744 Woods et al. Feb 2012 A1
20120059465 Brady et al. Mar 2012 A1
20120078361 Shadduck Mar 2012 A1
20120078363 Lu Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120116506 Compertore May 2012 A1
20120130487 Doraiswamy et al. May 2012 A1
20120130488 Doraiswamy et al. May 2012 A1
20120143327 Bumbalough Jun 2012 A1
20120150292 Mentak et al. Jun 2012 A1
20120203338 Jain Aug 2012 A1
20120232648 Kahook et al. Sep 2012 A1
20120232650 Hermans et al. Sep 2012 A1
20120232651 Kahook et al. Sep 2012 A1
20120245591 Matthews Sep 2012 A1
20120245684 Liao Sep 2012 A1
20120253458 Geraghty et al. Oct 2012 A1
20120253459 Reich et al. Oct 2012 A1
20120290084 Coroneo Nov 2012 A1
20120296425 Cumming Nov 2012 A1
20120296426 Brady et al. Nov 2012 A1
20120303119 Callahan et al. Nov 2012 A1
20120310338 Christie et al. Dec 2012 A1
20120310342 Nguyen et al. Dec 2012 A1
20120310343 Van Noy Dec 2012 A1
20120310344 Cumming Dec 2012 A1
20120310345 Olcina Portilla Dec 2012 A1
20120323320 Simonov et al. Dec 2012 A1
20120323321 Simonov et al. Dec 2012 A1
20120330415 Callahan et al. Dec 2012 A1
20130013060 Zadno-Azizi et al. Jan 2013 A1
20130018461 Ben Nun Jan 2013 A1
20130030525 Brady et al. Jan 2013 A1
20130035760 Portney Feb 2013 A1
20130053954 Rao et al. Feb 2013 A1
20130060330 Weeber et al. Mar 2013 A1
20130060331 Shadduck Mar 2013 A1
20130060332 Simpson Mar 2013 A1
20130073039 Mirlay Mar 2013 A1
20130103146 Smiley et al. Apr 2013 A1
20130103147 Christie et al. Apr 2013 A1
20130110235 Schwiegerling May 2013 A1
20130116781 Ben Nun May 2013 A1
20130131794 Smiley et al. May 2013 A1
20130138208 Simonov et al. May 2013 A1
20130150961 Evans et al. Jun 2013 A1
20130166026 Bumbalough Jun 2013 A1
20130184816 Hayes Jul 2013 A1
20130190868 Kahook et al. Jul 2013 A1
20130197635 Phillips Aug 2013 A1
20130204364 Olson Aug 2013 A1
20130204365 Dell Aug 2013 A1
20130226294 Van Der Mooren et al. Aug 2013 A1
20130226295 de Juan, Jr. et al. Aug 2013 A1
20130231741 Clarke Sep 2013 A1
20130231742 Deacon et al. Sep 2013 A1
20130238091 Danta et al. Sep 2013 A1
20130245754 Blum et al. Sep 2013 A1
20130245756 Liao Sep 2013 A1
20130250239 Hildebrand et al. Sep 2013 A1
20130268070 Esch et al. Oct 2013 A1
20130268071 Vilupuru et al. Oct 2013 A1
20130282117 Van Heugten et al. Oct 2013 A1
20130297018 Brady et al. Nov 2013 A1
20130304202 Basinger Nov 2013 A1
20130304203 Beer Nov 2013 A1
20130304204 Bumbalough et al. Nov 2013 A1
20130310931 Kahook et al. Nov 2013 A1
20130310932 Kellan Nov 2013 A1
20130317606 Culbertson et al. Nov 2013 A1
20130317608 Hermans et al. Nov 2013 A1
20130331937 Stevens Dec 2013 A1
20130338767 Mazzocchi et al. Dec 2013 A1
20130345713 Cole et al. Dec 2013 A1
20140005780 Zhao Jan 2014 A1
20140005781 Zhao et al. Jan 2014 A1
20140005782 Kellan et al. Jan 2014 A1
20140012277 Matthews et al. Jan 2014 A1
20140052245 Zickler et al. Feb 2014 A1
20140052246 Kahook et al. Feb 2014 A1
20140058507 Reich et al. Feb 2014 A1
20140142588 Hildebrand et al. May 2014 A1
20140180403 Silvestrini et al. Jun 2014 A1
20140180405 Weinschenk, III et al. Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140180407 Sohn et al. Jun 2014 A1
20140194859 Ianchulev Jul 2014 A1
20140249625 Shadduck Sep 2014 A1
20150087743 Anvar et al. Mar 2015 A1
20150088254 Cumming Mar 2015 A1
20150105760 Rao et al. Apr 2015 A1
20150134059 Curatu May 2015 A1
20150142108 Akura et al. May 2015 A1
20150202041 Shadduck Jul 2015 A1
20150238310 Matthews et al. Aug 2015 A1
20150257874 Hildebrand et al. Sep 2015 A1
20160030161 Brady et al. Feb 2016 A1
20160038278 Matthews Feb 2016 A1
20160128826 Silvestrini et al. May 2016 A1
20160157996 Dolla et al. Jun 2016 A1
20160184091 Smiley et al. Jun 2016 A1
20160184092 Smiley et al. Jun 2016 A1
20160262875 Smith et al. Sep 2016 A1
20160317286 Brady et al. Nov 2016 A1
20160317287 Silvestrini et al. Nov 2016 A1
20160361157 Honigsbaum Dec 2016 A1
20170020662 Shadduck Jan 2017 A1
20170049561 Smiley et al. Feb 2017 A1
20170079773 Matthews et al. Mar 2017 A1
20170247525 Silvestrini et al. Aug 2017 A1
20170290658 Hildebrand et al. Oct 2017 A1
20170342096 Silvestrini Nov 2017 A1
20180028308 Smiley et al. Feb 2018 A1
20180125640 Smiley et al. May 2018 A1
20180147051 Scholl et al. May 2018 A1
20180153682 Hajela et al. Jun 2018 A1
20180177639 Rao et al. Jun 2018 A1
20180256315 Hildebrand et al. Sep 2018 A1
20180271645 Brady et al. Sep 2018 A1
20180344453 Brady et al. Dec 2018 A1
20190000612 Rao et al. Jan 2019 A1
20190099263 Brady et al. Apr 2019 A1
Foreign Referenced Citations (126)
Number Date Country
2003294418 Jun 2004 AU
2003297101 Jun 2004 AU
2003300879 Jul 2004 AU
2004211746 Aug 2004 AU
2004219674 Sep 2004 AU
2005299661 May 2006 AU
2006265668 Jan 2007 AU
2006304339 Apr 2007 AU
2007340043 Jul 2008 AU
2008218313 Aug 2008 AU
2008279167 Jan 2009 AU
2008279173 Jan 2009 AU
2010235988 Nov 2010 AU
2010203427 Jul 2011 AU
2012335677 May 2014 AU
2014202532 Jul 2014 AU
2013235467 Sep 2014 AU
2015258287 Dec 2015 AU
2017216460 Aug 2017 AU
2016275073 Jan 2018 AU
2018200978 Mar 2018 AU
2016349532 Apr 2018 AU
2019201556 Mar 2019 AU
2506753 Jun 2004 CA
2508143 Jun 2004 CA
2507694 Jul 2004 CA
2515355 Aug 2004 CA
2584472 May 2006 CA
2613580 Jan 2007 CA
2626269 Apr 2007 CA
2674816 Jul 2008 CA
2676713 Aug 2008 CA
2693906 Jan 2009 CA
2696450 Jan 2009 CA
2748812 Jul 2010 CA
2854919 May 2013 CA
2865954 Sep 2013 CA
2987311 Dec 2016 CA
3001477 May 2017 CA
112010004191 Nov 2012 DE
1563337 Aug 2005 EP
1569581 Sep 2005 EP
1585563 Oct 2005 EP
1590702 Nov 2005 EP
1599748 Nov 2005 EP
1816984 Aug 2007 EP
1906882 Apr 2008 EP
1948084 Jul 2008 EP
2053991 May 2009 EP
2094193 Sep 2009 EP
2112932 Nov 2009 EP
2178462 Apr 2010 EP
2178463 Apr 2010 EP
2178464 Apr 2010 EP
2221024 Aug 2010 EP
2384167 Nov 2011 EP
2473138 Jul 2012 EP
2539351 Jan 2013 EP
2559405 Feb 2013 EP
2563275 Mar 2013 EP
2647353 Oct 2013 EP
2671541 Dec 2013 EP
2688515 Jan 2014 EP
2775961 Sep 2014 EP
2827804 Jan 2015 EP
2934383 Oct 2015 EP
2967842 Jan 2016 EP
3049023 Aug 2016 EP
3062741 Sep 2016 EP
3062742 Sep 2016 EP
3174500 Jun 2017 EP
3181094 Jun 2017 EP
3197462 Aug 2017 EP
3263574 Jan 2018 EP
3307206 Apr 2018 EP
3370647 Sep 2018 EP
3383320 Oct 2018 EP
1583193 Jan 1981 GB
1227277 Oct 2017 HK
1227679 Oct 2017 HK
1234303 Feb 2018 HK
1235658 Mar 2018 HK
1239501 May 2018 HK
1241712 Jun 2018 HK
1242207 Jun 2018 HK
6305DELNP2015 Jul 2016 IN
201617018083 Aug 2016 IN
201717013927 Aug 2017 IN
201617044673 Feb 2018 IN
2014061387 Apr 2014 JP
2012420 Sep 2014 NL
WO-2004046768 Jun 2004 WO
WO-2004052242 Jun 2004 WO
WO-2004054471 Jul 2004 WO
WO-2004072689 Aug 2004 WO
WO-2006047383 May 2006 WO
WO-2007005778 Jan 2007 WO
WO-2007047529 Apr 2007 WO
WO-2007047530 Apr 2007 WO
WO-2008024766 Feb 2008 WO
WO-2008077040 Jun 2008 WO
WO-2008082957 Jul 2008 WO
WO-2008103798 Aug 2008 WO
WO-2009015161 Jan 2009 WO
WO-2009015226 Jan 2009 WO
WO-2009015234 Jan 2009 WO
WO-2009015240 Jan 2009 WO
WO-2010081093 Jul 2010 WO
WO-2011026068 Mar 2011 WO
WO-2011106435 Sep 2011 WO
WO-2011137191 Nov 2011 WO
WO-2012006616 Jan 2012 WO
WO-20120106673 Aug 2012 WO
WO-2012129407 Sep 2012 WO
WO-2013070924 May 2013 WO
WO-2013142323 Sep 2013 WO
WO-2013166068 Nov 2013 WO
WO-2014099630 Jun 2014 WO
WO-2014134302 Sep 2014 WO
WO-2014145562 Sep 2014 WO
WO-2015148673 Oct 2015 WO
WO-2016018932 Feb 2016 WO
WO-2016049059 Mar 2016 WO
WO-2016201351 Dec 2016 WO
WO-2017079733 May 2017 WO
WO-2017085344 May 2017 WO
Non-Patent Literature Citations (7)
Entry
International Search Report and Written Opinion dated Dec. 4, 2013 in International Application No. PCT/US2013/039708.
Invitation to Pay Additional Fees dated Sep. 17, 2013 in International Application No. PCT/US2013/039708.
International Preliminary Report on Patentability and Written Opinion dated Nov. 20, 2014 in International Application No. PCT/US2013/039708 (13 pages).
Communication Pursuant to Rule 164(2) and Article 94(3) dated Oct. 11, 2018, for Application No. 13725509.7, 9 pg.
International Search Report and Written Opinion in PCT/US2017/048219 dated Jan. 2, 2018, 19 pages.
Communication Pursued to Article 94(3) EPC dated Oct. 11, 2018 in European Patent Application No. 13725509.7, 9 pages.
Communication Pursued to Article 94(3) EPC dated Apr. 2, 2019 in European Patent Application No. 17772509.0, 3 pages.
Related Publications (1)
Number Date Country
20180055626 A1 Mar 2018 US
Provisional Applications (1)
Number Date Country
62378737 Aug 2016 US